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Abstract 
Mycobacterium tuberculosis is presented with environmental host assaults that damage its 
DNA during infection. Tubercle bacilli possess mechanisms to protect against moststresses 
imposed by the host, including genotoxic stress. However, tolerance of DNA lesions that 
have escaped the normal repair processes requires the function of specialist DNA 
polymerases that can introduce mutations during translesion synthesis (replication by-pass), 
thus leading to damage-induced mutagenesis. Mycobacteria employ a novel DNA 
polymerase, DnaE2, for DNA damage tolerance and induced mutagenesis. DnaE2 belongs to 
the C-family of DNA polymerases, which are known to replicate DNA with high fidelity, and 
has been implicated in virulence and the emergence of rifampicin resistance of M. 
tuberculosis in vivo.  In this study, DnaE2 was shown to function in the same pathway as two 
accessory proteins, ImuB and ImuA’, for damage tolerance and induced mutagenesis in 
mycobacteria. In this system, DnaE2 performs the polymerase function in translesion 
synthesis whereas ImuB is a cryptic Y-family DNA polymerase that lacks critical active site 
residues. It contains a β-clamp binding motif that allows interaction with the β-clamp and 
presumably enables DnaE2 and ImuA’ to access the replication fork.  ImuB has a C-terminal 
region extending from the β-clamp binding motif which contains disordered regions that 
allow the interaction with other proteins and is important for function. ImuA’ is also essential 
for damage tolerance and induced mutagenesis but its function remains unknown. This 
protein is structurally similar to Escherichia coli RecA protein in the N-terminus and the 
middle domain, but it has a distinct C-terminus that was shown to be important for the 
interaction with ImuB. The essential replicative, C-family polymerase, DnaE1, was shown to 
be upregulated in response to DNA damage and was also shown to interact with ImuB. To 
explore the possibility that other proteins are involved in this pathway, ImuB was C-
terminally tagged for use as bait in pull-down experiments in M. smegmatis. However, 
introduction of the tag disrupted ImuB function, further reinforcing the importance of the C-
terminal region of ImuB for the function of this protein, presumably via protein-protein 
interactions. In contrast, a variant of ImuA’ which was N-terminally tagged was shown to 
retain functionality; however, experiments using this protein as a bait for pull-down proved to 
be unsuccessful. Proteomic analysis of wild type M. smegmatis, a dnaE2 deletion mutant and 
complemented derivative was carried out on cells exposed to the same conditions as used in 
the pull-down assay.  Base excision repair (BER) components were identified in this analysis, 
but did not detect ImuB and ImuA’, suggesting that the levels of expression of these proteins 
were comparatively lower under the conditions tested resulting in failure of the pull-down 
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experiment. Finally, numerous attempts were made to express and purify recombinant forms 
of ImuB and ImuA’ in E. coli for use in structural studies. Both proteins were expressed in 
the soluble and insoluble fractions; however the levels of soluble protein were low, and as a 
result, purified protein preparations could not be obtained.     
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Chapter 1 
1. Introduction 
Tuberculosis (TB) was declared a global health emergency by the World Health Organization 
(WHO) in 1993 yet continues to claim around 2 million lives per annum. One-third of the 
world’s population is infected with the causative agent, Mycobacterium tuberculosis, an 
obligate human pathogen. The TB burden is the highest in Asia and Africa with India and 
China accounting for almost 40 % of the world’s TB cases. The African region has 24 % of 
the world’s cases and the highest rates of cases and death per capita. South Africa is included 
amongst the countries with the highest world’s cases of drug resistant TB (WHO, 2012). 
There were 9.4 million new TB cases in 2009, of which 3.3 million were women, and 1.1 
million were in people co-infected with HIV (Barry et al., 2009; Russell et al., 2010; WHO, 
2010; Yang et al., 2007). Adding to this burden is the increasing emergence and spread of 
multi-drug (MDR) and extensively drug resistant (XDR) strains resistant to the major 
frontline and second-line anti-TB agents (Barry & Blanchard, 2010; Dye et al., 2002; 
Sacchettini et al., 2008). This pandemic is particularly alarming when one considers that TB 
is a curable disease.  
WHO introduced the Directly Observed Therapy - Short Course (DOTS) program in 1995, 
and it has been implemented worldwide (WHO, 2009). This strategy is cost-effective, 
requiring the use of a combination therapy consisting of an intense two-month treatment 
phase with the first-line drugs isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and 
pyrazinamide (PZA),  followed by a four-month continuation phase of INH and RIF (WHO, 
2009). It is estimated that nearly seven million lives have been saved compared with the pre-
DOTS era, with high cure rates having been achieved in most countries worldwide; the result 
is that the global incidence of TB has been in slow decline since early 2000s (Zumla et al., 
2012a). However, the emergence and spread of resistant strains of M. tuberculosis poses a 
threat to global TB control. Drug-resistant TB is a man-made problem resulting primarily 
from patient non-compliance to the extended chemotherapy (Zumla et al., 2012a). MDR-TB 
defined as resistance to INH and RIF is treatable with PZA, ethionamide, cycloserine, any of 
the injectable aminoglycosides (kanamycin, amikacin or capreomycin) and the 
fluoroquinolones (ciprofloxacin and ofloxacin) (WHO, 2009).This treatment is expensive, 
can last for up to two years and can be toxic to patients (Dye et al., 2002). This exacerbates 
non-compliance, and can lead to the emergence of XDR strains (Naidoo, 2007). XDR-TB, 
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which is defined as resistance to INH and RIF plus a fluroquinolone and any of the second-
line injectable agents, is virtually untreatable. The emergence of strains of M. tuberculosis 
that are resistant to a multiplicity of drugs with different mechanisms of action provides a 
cogent example of the capacity of the organism to adapt to, and overcome, the harsh 
conditions encountered during infection (Ehrt & Schnappinger, 2009; Ramakrishnan, 2012). 
According to the most recent WHO report, the Millennium Development Goals (MDG) target 
to halt and reverse the TB epidemic by 2015 has already been achieved. New cases of TB 
have been falling for several years and fell at a rate of 2.2 % between 2010 and 2011; 
moreover, the TB mortality rate has decreased 41 % since 1990 indicating that the world is 
on track to achieve the global target of a 50 % reduction by 2015. Even though the fight 
against TB seems promising, the global burden of TB remains enormous. In 2011, there were 
an estimated 8.7 million new cases of TB, of which 13% were co-infected with HIV, and 1.4 
million people died from TB, including almost one million deaths among HIV-negative 
individuals and 430 000 among people infected with HIV. Global progress also conceals 
major regional variations and disparities, with the African and European regions not on track 
to halve the levels of mortality by 2015 (WHO, 2012).  This situation demands the 
development of new tools to control TB, including novel anti-tubercular agents which might 
eradicate the infection caused by drug-susceptible and drug-resistant strains of M. 
tuberculosis. However, the reality is that resistance may develop to any new anti-tubercular 
drug. In 2009, the first report of totally drug-resistant (TDR) strains came out of Iran 
(Velayati et al., 2009); however, there are studies that seem to suggest that TDR was a pre-
existing form of XDR-TB (Migliori et al., 2012). With most of these drug-resistant strains 
genotyped as members of the Beijing, Haarlem and EAI super families (Velayati et al., 
2009), the TB epidemic has become even more alarming given that members of the Beijing 
super-family have also been associated with increased ability to cause and spread disease, as 
well as with co-infection with HIV (Caws et al., 2006; Hanekom et al., 2007; Johnson et al., 
2009).  
1.1 The current state of TB control 
As part of a global effort to eradicate TB, the WHO has implemented a program known as the 
“Global Plan to Stop TB 2006-2015”, which aims at reducing the 1990 prevalence of TB by 
50% by the year 2015 and the eventual eradication of the disease by 2050 (WHO, 2006). The 
program has the following targets: i) expanding and improving the DOTS program so that 
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supervised standardised treatment and effective drug management is implemented; ii) 
increasing TB/HIV collaborations, preventing and managing drug resistant M. tuberculosis 
strains and addressing the poor socio-economic conditions of the most vulnerable 
populations; iii) strengthening the primary health care sector; iv) engaging all communities 
(TB patients, care providers as well as the affected communities) to endorse the 
implementation and adherence of International Standards of Tuberculosis Care (ISTC); and 
v) promoting the development of novel and more effective TB diagnostic tools as well as 
therapies (WHO, 2006). All of these are points that the program seeks to achieve; however, a 
longer treatment course would lead to patient non-compliance and development of drug 
resistance, underscoring the need for the development of shorter drug regimens, as suggested 
(Salomon et al., 2006). The Global Plan to Stop TB 2011-2015 further seeks to improve on 
the following: i) laboratory strengthening-included as a major component; ii) fundamental 
research and operational research; iii) strategic frameworks to set out each major component 
of the plan in a clear and consistent format; iv) up-to-date epidemiological projections; v) 
updated targets for TB care and for research and development; vi) and updated funding 
requirements. With no new antibiotics introduced for the treatment of TB since the discovery 
of rifampicin in 1967, a number of programs have recently been implemented for the 
discovery and development of new TB drugs in order to achieve the Global Plan to Stop TB 
(Russell et al., 2010). Importantly, research plays a key role in efforts to eradicate the disease.  
1.1.1 Approaches to TB drug discovery 
As in other areas of anti-microbial drug discovery (Lamichhane, 2011; Payne et al., 2007; 
Raviglione et al., 2012; Sarker et al., 2012), the discovery of novel anti-mycobacterial drugs 
have been carried out using two approaches: phenotypic vs. target-led. The phenotypic 
approach is based on the screening of small-molecule libraries for compounds with the ability 
to kill mycobacteria using whole-cell screening assays. Mutants that are resistant to the 
compound are then used to identify the molecular target of the compound by means of whole-
genome sequencing. This approach has been quite successful, leading to the discovery of 
TMC207 (Bedaquiline) (Andries et al., 2005); the novel nitroimidazole derivatives, PA-824 
and OPC-67683 (Delamanid), which are in early-stage clinical development for drug-
resistant and drug-susceptible TB (Barry et al., 2004; Matsumoto et al., 2006), and the 
benzothiazinone, BTZ-043 (Cole & Riccardi, 2011; Makarov et al., 2009; Pasca et al., 2010; 
Sala & Hartkoorn, 2011). Both bedaquiline and the nitroimidazoles show promising activity 
against non-replicating organisms. However, limitation of whole-cell screens is that it has 
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produced only a small number of potential hits with moderate potency (Robertson et al., 
2012). 
 The second approach, which is target-led, is based on the identification of biochemical 
functions (usually enzymatic) that are essential for growth and survival of the organism, and 
the subsequent use of high-throughput biochemical screens to identify small-molecule 
inhibitors of the target’s function (Crunkhorn, 2012; Dover & Coxon, 2011; Zumla et al., 
2012b). The major challenge with this approach is that the potential hits that have potency 
against an essential enzyme may not efficiently penetrate the mycobacterial cell envelope. 
The other limitation is that the assumption that inhibition of an individual metabolic reaction 
will cause cell death may not be a complete description of the mode of action of an effective 
anti-bacterial agent (Dick & Young, 2011). Bactericidal activity may occur as a result of the 
downstream consequences of initial drug-target interaction which result in toxic molecules 
that act as true effector molecules (Dick & Young, 2011). For this reason, the identification 
of novel antimicrobials requires that both approaches should be used to mitigate the 
limitations  of each approach (Abrahams et al., 2012). From these approaches, a number of 
lead compounds with novel modes of action have been discovered in recent years (Lougheed 
et al., 2009). In addition to these agents developed specifically for TB, four drugs developed 
for other conditions are being re-purposed for TB (Bald & Koul, 2012; Koul et al., 2011; Ma 
et al., 2010). 
1.1.2 TB drugs and their mode of action against M. tuberculosis  
The complete genome sequence of M. tuberculosis (Calver et al., 2010) has enabled the 
identification of essential proteins as novel targets for drug development. The success of the 
target-based approach relies on the quality of the target as well as the level of validation 
(Chen & Du, 2007; Warner & Mizrahi, 2012). Only a few validated targets have been 
revealed to date. RpsA is a putative target for the old first-line TB drug, PZA. PZA has 
constituted a key component of the short-course therapy regimen since the 1980s without its 
cellular target being known until very recently. The ribosomal subunit, RpsA, was found to 
be a target of pyrazinoic acid – the active form of the pro-drug PZA. RpsA is a vital protein 
involved in protein translation and the ribosome-sparing process of trans-translation (Shi et 
al., 2011).  This target may thus provide a rationale for the activity of PZA and might help to 
explain the treatment-shortening activity of PZA (Bald & Koul, 2012; Scorpio & Zhang, 
1996; Shi et al., 2011). Arabinosyltransferase, a key component enzyme in arabinogalactan 
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synthesis, is the target of ethambutol (EMB) (Telenti et al., 1997).  Combination therapy is 
used for the treatment of MDR-TB using the aminoglycosides, kanamycin and amikacin, 
together with the cyclic peptide, capreomycin. Aminoglycosides target the 16S rRNA 
whereas capreomycin targets rRNA methyltransferase (Gillespie, 2002; Johansen et al., 
2006). The rpoB-encoded β-subunit of RNA polymerase has been shown to be the target of 
rifampicin (Telenti et al., 1993). Fluoroquinolones have been shown to target DNA gyrase. 
Isoniazid (INH) targets the InhA protein (Vilcheze et al., 2006). Ethionamide is similar to 
isoniazid in that it is a pro-drug that requires activation to form an adduct with NAD that 
subsequently inhibits the NADH-dependent enoyl-(acyl-carrier protein) reductase InhA 
(Hazbon et al., 2006). Streptomycin targets the rpsL-encoded S12 ribosomal protein and p-
amino salicyclic acid targets the folate pathway (Chakraborty et al., 2012; Gillespie, 2002; 
Rengarajan et al., 2004). The nitroimidazoles , PA-824 and OPC-67683, are pro-drugs that 
require activation by a deazaflavin (cofactor F420) dependent nitroreductase, Ddn 
(Manjunatha et al., 2009; Manjunatha et al., 2006; Matsumoto et al., 2006). More recently, 
the promising drug, bedaquiline, which is active against drug-susceptible and drug-resistant 
M. tuberculosis, targets ATP synthase (Andries et al., 2005; Manjunatha et al., 2006; 
Sacksteder et al., 2012) which the bacteria uses to generate energy (Bald & Koul, 2010; 
Hurdle et al., 2011).  
New TB drugs, at various stages of clinical development include rifapentine (a member of the 
rifamycin drug class) and the fluoroquinolones, gatifloxacin and moxifloxacin (Bald & Koul, 
2012; Koul et al., 2011), as well as linezolid (Koh et al., 2012; Sotgiu et al., 2012). 
Rifapentine, a bacterial RNA polymerase inhibitor, which is more effective than rifampicin in 
vitro and has a longer serum half-life, would be an ideal replacement candidate for rifampicin 
for use in the treatment of drug-susceptible TB. This drug is currently in Phase II clinical 
trials to assess if it could be given once or twice weekly as a replacement for the daily intake 
of the first-line antibiotic rifampicin (Ma et al., 2010; Sacchettini et al., 2008). Linezolid is a 
member of the oxazolidinones which are compounds that bind to the 50S ribosomal subunit 
inhibiting the subsequent formation of the 70S ribosome, thereby effectively inhibiting 
protein synthesis (Barry & Blanchard, 2010; Ma et al., 2010). 
Although linezolid, which is currently in phase II clinical trials, is associated with high 
toxicity levels, this drug has been successfully used off-label for the treatment of MDR- and 
XDR-TB (Barry & Blanchard, 2010; Lee et al., 2012; Ma et al., 2010; Sacchettini et al., 
2008). Gatifloxacin and moxifloxacin, which target the bacterial DNA gyrase, have proven to 
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be more effective than the current second-line drugs ofloxacin and ciprofloxacin in the 
treatment of TB. Currently, phase III clinical trials are underway to ascertain whether these 
drugs can be used to shorten first-line therapy to 4 months by replacement of ethambutol or 
isoniazid (Barry & Blanchard, 2010; Diacon et al., 2012a; Ma et al., 2010; Sacchettini et al., 
2008). 
There are six new compounds, specifically identified for TB treatment, that are currently in 
clinical development. Three of these are in Phase I clinical trials. The first, PNU-100480 is an 
oxazolidinone that exhibits greater activity than linezolid against M. tuberculosis in a murine 
model (Ford et al., 2001; Ma et al., 2010; Pinon et al., 2010; Sacchettini et al., 2008). The 
second drug AZD-5847, also an oxazolidinone, is active against drug-resistant forms of M. 
tuberculosis (Ma et al., 2010); and SQ-109 on the other hand, is an ethylenediamine that 
interacts synergistically with isoniazid and rifampicin against M. tuberculosis in a murine 
model (Barry & Blanchard, 2010; Ma et al., 2010; Sacchettini et al., 2008). SQ-109 targets 
MmpL3, which is a mycolic acid transporter required for incorporation of mycolic acid into 
the cell wall of M. tuberculosis (Grzegorzewicz et al., 2012; Tahlan et al., 2012). The other 
new drugs, namely, bedaquiline and delamanid, are currently in Phase II trials (Diacon et al., 
2012b; Gler et al., 2012). Bedaquiline has shown great efficacy against susceptible and 
resistant M. tuberculosis strains both in vitro and in vivo (Anantharaman & Aravind, 2003; 
Barry & Blanchard, 2010; Diacon et al., 2012a; Ma et al., 2010; Sacchettini et al., 2008; 
Tasneen et al., 2011).  
PA-824 and OPC-67683 are nitrofuranylamides, with OPC-67683 referred to as a delamanid 
that have potent activity against M. tuberculosis. Both drugs are pro-drugs that require 
enzymatic reduction to generate active forms (Maroz et al., 2010; Matsumoto et al., 2006; 
Singh et al., 2008). There is substantial cross-resistance between these two agents, implying 
that they have a similar if not identical mechanism(s) of action (Hurdle et al., 2011). Both 
agents have activity in the mouse model, although OPC-67683 may be more potent 
(Matsumoto et al., 2006). When added to rifampin and pyrazinamide, either PA824 or OPC-
67683 allows shortening of TB treatment in the mouse model to 3–4 months (Tasneen et al., 
2008). This indicates the potential to reduce the time needed to develop new anti-tuberculosis 
regimens (Diacon et al., 2012a). It is important to note that bedaquiline, moxifloxacin and the 
nitroimidazoles, which target replicating and non-replicating bacilli, have also enabled the 
development and validation of various in vitro models for testing the efficacy of new TB 
drugs under stressful conditions encountered within the host (Cho et al., 2006; Ehrt & 
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Schnappinger, 2009; Ramakrishnan, 2012); for example, under conditions of hypoxia in the 
presence and absence of reactive nitrogen intermediates (Barry & Blanchard, 2010; Hussain 
et al., 2009; Ma et al., 2010; Sacchettini et al., 2008). Even though there are promising drugs 
currently in various stages of clinical development, there is concern that drug resistance 
might subvert any new chemotherapeutic regimen. 
 
1.2 M. tuberculosis encounters variable microenvironments during host infection  
M. tuberculosis bacilli are inhaled into the lungs inside the human host where they experience 
a variety of stresses from the host immune system. Inside the host, the bacilli are internalized 
by alveolar macrophages which should kill the bacteria (Peyron et al., 2008). The interaction 
of the bacilli and the receptors of the immune cells results in an intracellular signaling 
cascade that culminates in a proinflammatory response (van Crevel et al., 2002).  
Mycobacteria have evolve strategies that can trigger signals that dampen or modulate the 
innate immune response indicating that killing of the bacterium depends on the intrinsic 
microbicidal capacity of the host phagocytes and virulence factors of the ingested 
mycobacteria (Ahmad, 2011). The alveolar macrophages produce inflammatory cytokines 
and chemokines that serve as a signal for infection, thus allowing migration of monocytes, 
neutrophils and lymphocytes to the focal site of infection resulting in granuloma formation 
(Peyron et al., 2008). During this time, the bacilli resist the bactericidal mechanisms of the 
macrophage by preventing phagosome-lysosome fusion, and continue to multiply inside the 
macrophage ultimately causing macrophage necrosis. The released bacteria are also engulfed 
by another macrophage and the whole process is repeated. In healthy individuals, the 
interplay between M. tuberculosis and host cellular and adaptive immune cells results in 
asymptomatic infection as granulomas separate M. tuberculosis cells from the surrounding 
tissue, and the mycobacteria become latent (Stewart et al., 2003). The ability of M. 
tuberculosis to interact and manipulate host immune functions allows latent infection to 
continue. Traditionally, it was thought that granulomas were protective against TB, however 
recent evidence indicates that M. tuberculosis may actually recruit immune cells to form 
granulomas, wherein the bacilli are able to persist in a protected environment until conditions 
are favorable for reactivation and dissemination (Davis & Ramakrishnan, 2009; 
Ramakrishnan, 2012). Granuloma formation walls off the tubercle bacilli, providing a 
variable microenvironment. 
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Latent TB infection is associated with the formation of at least two types of tuberculous 
granuloma (Barry et al., 2009; Lin et al., 2009). The classic caseous granuloma are composed 
of epithelial macrophage, neutrophils, and other immune cells surrounded by fibroblasts 
where the centre of the caseous necrotic region is hypoxic with M. tuberculosis residing in 
the hypoxic centre (Barry et al., 2009; Via et al., 2008). The other kind of granuloma seen in 
latent TB infection is fibrotic lesion composed almost exclusively of fibroblasts that contain 
very few macrophages. However, it is not clear whether M. tuberculosis is located inside 
macrophage or in the fibrotic area in the lesion (Ahmad, 2011). Within the macrophages it 
has been believed that latency is propagated by nutrient deprivation, hypoxia, nitric oxide, 
carbon monoxide and acid pH (Ghosh et al., 2009; Kumar et al., 2008; Rustad et al., 2009; 
Ulrichs & Kaufmann, 2006) .    
1.2.1 Evidence for genotoxic stress during host infection 
During infection, the bacilli are subjected to damage by exogenous and endogenously 
generated oxidants and radicals such as reactive oxygen and reactive nitrogen intermediates 
(ROI and RNI, respectively) that are toxic to the pathogen (Darwin & Nathan, 2005). ROI 
and RNI can damage lipids, protein and nucleic acids (Sies & Cadenas, 1985; Sies & 
Mehlhorn, 1986). The activated macrophages express two enzymes, phagocyte oxidase  
(NOX2/gp91phox) and inducible nitric oxide synthase (iNOS), which produce increased 
quantities of ROI and RNI that constitute the  major stressor of M. tuberculosis in vivo (Ehrt 
& Schnappinger, 2009). Upon phagocytosis, NOX2 subunit assembles into an enzymatically 
active enzyme complex that transfers electrons across the membrane from cytosolic NADPH 
to molecular oxygen. This produces superoxide anions (O2-), which dismutate into hydrogen 
peroxide (H2O2) and generate toxic hydroxyl radicals (Bedard & Krause, 2007). The toxic 
effects imposed by the immune system can be limited by mechanisms such as reducing the 
expression of the iNOS in the host, thus allowing the bacilli to minimize the damaging effects 
of iNOS in vivo (Darwin & Nathan, 2005; Ehrt et al., 2001; MacMicking et al., 1997). 
Induction of high amounts of iNOS usually occurs in an oxidative environment, and thus high 
levels of nitric oxide (NO) have the opportunity to react with superoxide leading to 
peroxynitrite formation and cell toxicity. These properties may define the roles of iNOS in 
host immunity, enabling its participation in anti-microbial and anti-tumor activities as part of 
the oxidative burst of macrophages (Cole et al., 2012; Mungrue et al., 2002). An in vitro 
study utilized mildly acidified nitrite, a physiological source of NO, to screen for M. 
tuberculosis mutants with an impaired ability to survive the damaging effects of this 
9 
 
environment (Cho et al., 2006; Ehrt & Schnappinger, 2009; Ramakrishnan, 2012). Among 
the mutants identified in the screen, two carried mutations in the nucleotide excision repair 
(NER) gene, uvrB, which resulted in profound sensitivity to acidified nitrite which mimics 
the environment within the host (Ramakrishnan, 2012). Studies prior to this indicated that a 
recA mutant of Mycobacterium bovis bacillus Calmette-Guerin (BCG) had no detectable 
phenotype in a mouse model for up to 80 days post infection (Sander et al., 2001) whereas a 
dnaE2 mutation attenuated M. tuberculosis in wild type C57BL/6 mice but did not affect 
bacterial load until late in the infection suggesting that mycobacteria have the ability to 
employ tolerance mechanisms in order to withstand the ongoing DNA damaging effects 
imposed by the environment (Boshoff et al., 2003). RecA plays a role in DNA damage 
response by promoting autocleave of the LexA repressor protein that regulate expression of 
SOS response protein whereas DnaE2 has been shown to be involved in mycobacterial SOS 
response by performing translesion synthesis (Boshoff et al., 2003; Warner et al., 2010). 
Thus, although recA and dnaE2 mutants had increased susceptibility to DNA damaging 
agents in vitro, they had distinct phenotypes in the mouse. This indicates that there is 
interplay between DNA repair/ damage tolerance that plays a role in survival and 
pathogenesis in M. tuberculosis.  
1.2.2 A role for DNA repair in M. tuberculosis pathogenesis 
DNA repair plays a fundamental role in maintenance of genome stability in order to remain 
fit and able to establish an infection, grow and persist within a host. M. tuberculosis contains 
all DNA repair mechanisms found in other bacteria except the mismatch repair (MMR) 
mechanism which plays a key role in post replication mismatch repair. This finding is 
interesting since it suggests that the fidelity of replication is compromised or there exists an 
alternative mechanism(s) to correct replication errors (Mizrahi & Andersen, 1998). M. 
tuberculosis has adapted to the lack of MMR by utilizing other repair systems in which the 
UvrD1 protein of the nucleotide excision repair (NER) system functions in the processing of 
mismatches by homologous recombination (Guthlein et al., 2009). 
NER was first identified as a pathway that repairs DNA lesions such as thymine dimers 
resulting from exposure to UV radiation. DNA damage such as abasic sites, DNA cross-links, 
strand breaks and deaminated bases generated by ROS and RNI and are also substrates for 
NER. In human mycobacteria isolated from macrophages and lung samples, genes involved 
in NER pathway were shown to be upregulated (Graham & Clark-Curtiss, 1999; Rachman et 
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al., 2006). Recently, a M. tuberculosis mutant deficient in UvrA was reported to be sensitive 
various DNA damaging agents (Rossi et al., 2011) and another key member of the NER 
system – the UvrB protein – was shown to be important for bacterial survival both in vitro 
and in vivo (Darwin & Nathan, 2005; Kurthkoti & Varshney, 2011). Mycobacteria possess 
most of the conserved proteins that participate in base excision repair (BER) pathway except 
for RecJ, reinforcing the importance of excision repair pathways which the cell can use to 
prevent unwanted mutations by removing the vast majority of DNA damage imposed by the 
host environment (Kurthkoti & Varshney, 2011; Mizrahi & Andersen, 1998; Prammananan et 
al., 2012). A number of studies have been done in M. smegmatis to show that the lack of 
these repair processes renders the cell sensitive to genotoxic stresses modelled on that 
encountered by M. tuberculosis in the host (Cordone et al., 2011; Dick et al., 1998; Dutta et 
al., 2010; Gorna et al., 2010; Lim & Dick, 2001; Nyka, 1974; Wayne & Hayes, 1996). 
The toxic effects of the host can also be overcome by the use of recombination and end-
joining repair processes which are able to repair double-stranded breaks in the chromosome 
to ensure bacillary viability. Amongst other bacteria, mycobacteria have been shown to 
utilize the non-homologous end joining (NHEJ) pathway which was originally thought to be 
limited to eukaryotes (Gong et al., 2005; Weller et al., 2002). A recent study has reported the 
unexpected identification of an active single-strand annealing (SSA) pathway in M. 
smegmatis to repair chromosomal double-strand breaks (DSBs) (Gupta et al., 2011). SSA is a 
RecA-independent mechanism which requires LigD, a component of the NHEJ system. Prior 
to this study, DSB repair was catalysed by two mechanisms, homologous recombination 
(HR) and non-homologous end-joining pathways (NHEJ). HR is generally an error-free 
processes since it utilizes the non-damaged sister chromatid to direct repair whereas in 
bacteria including mycobacteria, a remarkably compact version of NHEJ is utilized in which 
all of the required activities are performed by only two proteins, a Ku homodimer and the 
multifunctional ligase/polymerase/nuclease LigD (Della et al., 2004). The M. tuberculosis 
genome also contains a number of other predicted ligases whose potential role in NHEJ 
processes is unclear (Aniukwu et al., 2008). The organism has LigA which is an essential 
replicative ligase (Gong et al., 2005). Moreover, recent data have shown that a Sir2-like 
NAD-dependent deacetylase functionally interacts with Ku during NHEJ (Li et al., 2011), 
suggesting that multiple interacting components might mediate NHEJ activity and function.   
In addition to the threat posed to genome integrity, DNA lesions which hinder the function of 
RNA polymerase can have detrimental consequences for cellular homeostasis and survival. 
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Stalling of RNA polymerase triggers the transcription-couple repair (TCR) pathway which is 
an important subclass of NER that ensures that actively transcribed genes are repaired more 
rapidly than inactive regions of the genome. In bacteria including M. tuberculosis, TCR is 
mediated by the mfd (mutation frequency decline)-encoded protein (Prabha et al., 2011) 
which is a homologue of the eukaryotic transcription-repair coupling factor (TCRF). In M. 
tuberculosis, Mfd does not recognize DNA damage directly, but through its interaction with 
the N-terminus of the RNA polymerase β subunit (Westblade et al., 2010) it initiates a 
cascade of events which ensures the removal of the stalled RNA polymerase from the site of 
damage and recruitment of the NER components to effect the necessary repair. 
1.3 DNA damage tolerance 
Despite the existing repair mechanisms, some DNA lesions persist in the genome and 
compromise survival of the organism.  Bacteria have evolved mechanisms that are able to 
overcome the detrimental effects of the unrepaired DNA lesions, but with the consequence of 
generating mutations. Such mechanisms utilize specialized translesion synthesis (TLS) 
polymerases that replicate past lesions (Yang & Woodgate, 2007). The classical specialized 
DNA polymerases that belong to the Y family of polymerase are structurally distinct from 
normal replicative polymerases in that they are capable of accommodating and replicating 
across lesions in DNA that obstruct progress by the normal replicative polymerase 
(Andersson et al., 2010; Yang & Woodgate, 2007), and thus perform an important function in 
maintaining bacterial viability. It is important to note that not all TLS polymerases are error-
prone because some have the ability to maintain high replication fidelity by incorporating the 
nucleotide that normally pairs with the undamaged nucleotide when replicating across a 
cognate lesion (Andersson et al., 2010).  While these polymerases can display high fidelity of 
replication across cognate lesions, their replication fidelity across non-cognate lesions or on 
undamaged templates is often reduced (Yang & Woodgate, 2007). For this reason, TLS 
function is often associated with mutagenesis (Andersson et al., 2010). This is a phenomenon 
well studied in Escherichia coli, where TLS polymerases form part of the SOS response 
which up-regulates more than 40 genes following DNA damage (Erill et al., 2006; Tippin et 
al., 2004). In E. coli, the polymerases that are involved in the SOS response are DNA 
polymerase II, IV and V. M. tuberculosis has homologues of the Pol IV-type Y family 
polymerases, but these are not to induced in response to DNA damage (Boshoff et al., 2003; 
Brooks et al., 2001; Kana et al., 2010). Instead, a C-family polymerase, DnaE2 was shown to 
be up-regulated in response to DNA damage (Boshoff et al., 2003; Kana et al., 2010). 
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Importantly, DnaE2 belongs to the C-family of DNA polymerases, which includes replicative 
polymerase, DnaE1. 
It is worth mentioning that damage tolerance mechanisms can result in error-free or error-
prone repair. In E. coli, Polymerase II is also used for TLS across abasic lesions when SOS is 
turned on in the absence of induction of the GroELS heat shock proteins (Tessman et al., 
1992), while error-prone polymerase V is responsible for error-free acetylaminofluorene 
(AAF) adduct bypass (Napolitano et al., 2000). Polymerase ζ, a B-family polymerase from 
mammalian cells is able to incorporate efficiently two A nucleotides opposite a TT (6-4) 
photoproduct in vitro, resulting in error-free bypass of the lesion, but its function is dependent 
on the presence of Rev1 protein in a two-polymerase mechanism (Goodman, 2002; 
Rechkoblit et al., 2002).  Polymerase ζ cooperates with Rev1 to accomplish TLS past abasic 
site, with polymerase ζ extending from the mispaired C opposite the abasic site. Rev1 
exhibits a second property in addition to deoxycytidyltransferase activity by acting in 
combination with polymerase ζ to achieve error-free bypass.  Rev1 protein is the first 
recognized Y-family member which acts as a deoxycytidyltransferase that incorporates 
dCMP opposite abasic sites in yeast and humans (Lin et al., 1999; Nelson et al., 1996). 
Another example of error-free bypass is that performed by the Y-family polymerase κ in vitro 
and in mammalian cells. This polymerase is able to bypass bulky lesions linked to the amino 
group of guanine that resides in the B-DNA minor groove. The capability of this polymerase 
has been demostrated to bypass adducts caused by an environmental carcinogenic agent 
benzo[a]pyrene (B[a]P) present in tobacco smoke, automobile exhaust and cooked foods 
(Lior-Hoffmann et al., 2012; Phillips, 1983) in an error-free manner (Huang et al., 2003; 
Rechkoblit et al., 2002; Zhang et al., 2000; Zhang et al., 2002).   
1.3.1 Structural insight into Error-prone and Error-free lesion Bypass 
The structure of the polymerase can determine whether a particular polymerase will replicate 
DNA in an error-free manner by performing highly accurate and processive DNA replication 
together with the exonuclease activity to enhance replication fidelity. Alternatively, 
replication can occur in an error prone fashion, with low processivity and lacking 
exonuclease activity. Several crystal structures of error-prone Y-family DNA polymerases 
have been solved from which valuable insights into their mode of action can be drawn. A 
crystal structure of the N-terminal region that includes the active site of Saccharomyces 
cerevisiae pol η has been determined and apart from containing the overall shape of DNA 
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polymerase, it contained a novel polymerase-associated domain (PAD), which mimics an 
extra set of fingers with the palm domain nearly superimposable with that of the high-fidelity 
polymerases. The PAD domain is also referred to as the little finger domain that contains the 
β-clamp binding domain. The O helices believed to be important for fidelity checking are 
absent in pol η (Marx & Summerer, 2002). Further insight into error-prone was gained 
through the crystal structure of Sulfolobus solfataricus P2 DNA polymerase IV (Dpo4) which 
can bypass cis-syn CPD lesions efficiently and thus, with respect to TLS, the enzymatic 
properties of Dpo4 are similar to that of the eukaryotic pol η (Ling et al., 2001). The Dpo4 
structure was successfully obtained in ternary complexes with the DNA primer template and 
either a canonical or non-canonical incoming nucleoside triphosphate showing a familiar 
shape of a half open right hand found in several polymerases. Dpo4 contains a little finger 
domain in addition to the finger, palm, and thumb domains. Again, the palm domain of Dpo4 
is similar to high fidelity DNA polymerases with finger and thumb domains of both pol η and 
Dpo4 unusually small and O helices absent (Marx & Summerer, 2002). 
Apart from the structural features of the polymerases that perform DNA replication, the site 
of adducts in the DNA is also a determinant of whether it will be repaired in an error-free or 
error-prone way. NMR solution studies have shown that the B[a]P-dG adduct resides in the 
B-DNA minor groove, directing the 5’ in-coming nucleotide along the modified strand (Lior-
Hoffmann et al., 2012). While minor groove lesions are bypassed nearly error-free by 
polymerase κ, lesions residing on the major groove side tend to cause the polymerase to stall 
(Jia et al., 2008; Rechkoblit et al., 2002; Sherrer et al., 2012).  
1.4 Mechanism of the SOS response 
During normal growth, SOS genes are negatively regulated by the LexA repressor protein 
which binds to a 20-bp consensus sequence (the SOS box) in the operator region of those 
genes under SOS regulation. Some SOS genes are expressed even in the repressed state, 
depending on the affinity of LexA for the corresponding SOS box (Smith & Walker, 1998). 
Activation of the SOS genes occurs after DNA damage by the accumulation of single-
stranded DNA (ssDNA) regions generated at replication forks, where the DNA polymerase is 
blocked. RecA forms a filament around these ssDNA regions in an ATP-dependent manner, 
and becomes activated. The activated form of RecA interacts with the LexA repressor to 
facilitate LexA self-cleavage, thus de-repressing the genes in the SOS regulon (Smith & 
Walker, 1998). 
14 
 
Once the pool of LexA decreases, repression of the SOS genes goes down according to the 
level of LexA affinity for the SOS boxes. Operators that bind LexA weakly are the first to be 
fully expressed. In this way, LexA can sequentially activate different mechanisms of repair. 
In E. coli, genes possessing a weak SOS box (such as lexA, recA, uvrA, uvrB, and uvrD) are 
fully induced in response even to weak SOS-inducing treatments. Thus, the first SOS repair 
mechanism to be induced is NER, ensuring high-fidelity repair of DNA damage without 
commitment to a full-blown SOS response (Smith & Walker, 1998). 
If, however, NER alone is not sufficient to repair the damage, the LexA concentration is 
further reduced, so the expression of genes with stronger LexA boxes (such as sulA, umuD, 
umuC – these are expressed late) is induced. SulA inhibits cell division by binding to FtsZ, 
the initiating protein in this process (Chen et al., 2012; Cordell et al., 2003; Trusca et al., 
1998). This causes filamentation, and the induction of components of polymerase V, 
UmuD׳2C, which can result in mutagenic repair. As a result of these properties, some genes 
may be partially induced in response to endogenous levels of DNA damage, while other 
genes appear to be induced only when high or persistent DNA damage is present in the cell 
(Patel et al., 2010; Smith & Walker, 1998). Research has shown that the SOS pathway may 
be essential to the acquisition of bacterial mutations which lead to resistance to some 
antibiotic drugs (Cirz et al., 2005; Cirz & Romesberg, 2007). In these studies, the increased 
rate of mutation was shown to be dependent on the activity of the three SOS DNA 
polymerases: Pol II, Pol IV and Pol V. 
Genome integrity is crucial to the survival and propagation of the organism, and therefore, 
there is a balance between DNA repair and damage tolerance pathways. DNA repair 
pathways ensure error-free repair whereas damage tolerance mechanisms allow selection of a 
bacterial population that is able to withstand the damaging effects, sometimes generating 
genetic diversity. The interplay between these opposing forces in turn impacts the relative 
fitness of the organism. The inferred importance of DNA repair for pathogenesis suggests 
some pathway components as potential targets for novel antibacterials. In theory, compounds 
could be designed to target repair components functioning in essential repair and maintenance 
pathways or those providing environment-dependent damage tolerance mechanisms (Cirz et 
al., 2005; Cirz & Romesberg, 2007; Warner, 2010). The process of replication, repair and 
recombination favours the maintenance of genome stability whereas adaptive mutation, 
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which results from low fidelity damage tolerance, can fuel the evolution of pathogenic 
bacteria including M. tuberculosis (McGuire et al., 2012).   
1.5 Importance of tolerance mechanisms 
Genome stability is important for propagation and maintenance of bacterial population; 
however, the environmental factors also play a role in genome diversity and selection. 
Introduction of mutations in the genome allows selection of a population that has inherited 
those mutations to enable survival in that particular environment. In many bacteria, drug 
resistance determinants are carried on mobile genetic elements. In contrast, the emergence of 
drug resistance in M. tuberculosis is associated exclusively with point mutations and 
chromosomal re-arrangements (Musser et al., 1996; Musser et al., 1999; Sandgren et al., 
2009), a feature that is thought to result in part from the ecological isolation of M. 
tuberculosis during host infection (Gillespie, 2002; Gillespie et al., 2002). There are also 
non-heritable tolerance mechanisms that do not require acquisition of mutations in the 
genome in order to withstand environmental effects. Such mechanisms include the ability to 
form biofilms (Donlan & Costerton, 2002), permeability barriers (Nikaido, 1994; Nikaido, 
2001) and persister formation (Dorr et al., 2010). Of particular importance in the case of TB 
is the emergence of drug resistant strains which indicate the astonishing ability of M. 
tuberculosis to survive in the presence of the antitubercular drugs and also pose a challenge 
for completely eradicating the disease using chemotherapy.  
The appearance of antimicrobial resistance is an inevitable consequence of the selective 
pressure imposed by antimicrobial therapy (Cirz et al., 2005) resulting in spontaneous genetic 
mutations which confers resistance to a drug, thus driving evolution. This Darwinian 
principle of selection underlies the application of combination therapy. M. tuberculosis is 
subjected to harsh environmental conditions during infection, as well as antibiotic treatment 
in patients, once diagnosed. If the antibiotics are not appropriately delivered into the target 
site and not managed appropriately, they create a sub-lethal concentration that has the 
potential to select for the gradual evolution of resistance through the sequential acquisition of 
resistance-determining mutations.  A potential strategy to counter the adaptive evolution of 
M. tuberculosis during host infection – including the development of drug resistance – 
involves targeting mutagenic pathways underlying the evolution of drug resistance. 
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1.6 Emergence of drug resistant mutants through adaptation 
Stationary-phase and stress-induced mutagenesis in bacterial adaptation has been associated 
with the emergence of drug-resistant strains of pathogenic bacteria (Phillips, 1987), and 
might be of particular relevance to the generation of antibiotic and other stress resistance 
mutations in M. tuberculosis within the hostile environment (Gutacker et al., 2002a; Gutacker 
et al., 2002b; Ramaswamy & Musser, 1998). Mutation in general may be detrimental to a cell 
as it might decrease the fitness of the organism (Friedberg et al., 2002). This was 
demonstrated in competition experiments between E. coli mutants lacking any of the TLS 
polymerases and wild-type cells: the cells lacking the TLS polymerase suffer a severe 
reduction in fitness in stationary phase suggesting that TLS polymerases are essential to 
prevent the appearance of adaptive mutations during prolonged stationary phase where 
cytotoxic alkylation damage accumulates (Andersson et al., 2010; Bjedov et al., 2007; Yeiser 
et al., 2002). 
TLS polymerases typically have low fidelity when replicating non-cognate DNA and are 
therefore under tight regulation. However, they must be readily available at the stalled 
replication fork to prevent obstruction of replication, and hence, are often induced in response 
to DNA damage as part of an SOS response (Goodman, 2002; Yang & Woodgate, 2007). 
Notably, Y-family polymerases do not usually have exonuclease activity, with the exception 
of the B-family polymerase that has exonuclease activity.  Furthermore, while replicative 
polymerases utilize a mechanism that ensures correct base pairing at the active site, Y-family 
DNA polymerases have flexible active sites that permit bypass of distorting lesions with a 
consequent loss of fidelity (Bunting et al., 2003; Napolitano et al., 2000; Wagner et al., 
1999). The C-family polymerases are primarily bacterial replicative enzymes. A well-studied 
polymerase belonging to this group is DNA Polymerase III. It functions as a holoenzyme 
comprising α (polymerase), ε and θ subunits. DNA polymerase III holoenzyme is the primary 
enzyme complex involved in prokaryotic DNA replication. The complex has high 
processivity (i.e. the number of nucleotides added per binding event) and, in E. coli, functions 
in conjunction with four other DNA polymerases (Pol I, Pol II, Pol IV, and Pol V). Being the 
primary holoenzyme responsible for replication, the DNA Pol III holoenzyme also has 
proofreading capabilities that corrects replication mistakes by means of exonuclease activity 
working in a 3'→5' direction. DNA Pol III is a component of the replisome, which is located 
at the replication fork.  
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The replisome is composed of a hexameric DnaB helicase that encircles the lagging strand 
and uses ATP to translocate along single-strand DNA and separate the parental duplex. The 
clamp loader pentamer contains at least two τ subunits which have C-terminal extensions that 
protrude from the top of the clamp loader with each of the C-terminal extensions binding to a 
DnaB helicase subunit. In addition, to these components, there are two Pol III cores 
comprising the α subunit which possess the polymerase activity, the ε subunit which has 
3'→5' exonuclease activity, and the θ subunit which stimulates proofreading by the ε subunit. 
The two τ subunits act to dimerize the two core enzymes together with one γ unit of the 
clamp loader for the lagging strand Okazaki fragments, thus helping the two β subunits to 
form a unit and bind to DNA. The assembly containing the clamp loader and two molecules 
of Pol III binds a β-clamp to form a holoenzyme. Two β subunits act as sliding DNA clamps 
that keep the polymerase bound to the DNA.  The one Pol III functions in the leading strand 
and the other in the lagging strand, with the lagging strand requiring synthesis of RNA primer 
templates by primase interacting with DnaB (Georgescu et al., 2010; Langston & O'Donnell, 
2006). Two distinct Pol IIIs are required for synthesis with PolC serving as the polymerase 
for leading strand synthesis, and DnaE synthesizing the lagging strand in the Gram+ 
organism, Bacillus subtilis (Kelman & O'Donnell, 1995; Olson et al., 1995; Sanders et al., 
2010). The polymerases, either belonging to the Y family or C family, require interactions 
with the β clamp to access template DNA. This allows efficient switching between replication 
and repair modes for efficient lesion by-pass (Friedberg et al., 2005; Langston & O'Donnell, 
2006). 
1.7 SOS response in Mycobacteria 
Although an SOS response has been identified in mycobacteria  (Davis et al., 2002; Durbach 
et al., 1997), it is unusual in that none of the predicted Y-family polymerases is included in 
the damage response regulon (Boshoff et al., 2003; Kana et al., 2010; Smollett et al., 2012). 
Instead, Boshoff et al. (Boshoff et al., 2003) showed that the only DNA polymerase that was 
induced in transcriptome analysis of M. tuberculosis after exposure to various DNA 
damaging agents was DnaE2. Subsequent to that study, DnaE1 was also shown to be up-
regulated in response to DNA damage (Warner et al., 2010).  Although the M. tuberculosis 
genome contains two genes encoding the catalytic (α) subunit of DNA Pol III, the encoded 
proteins, DnaE1 and DnaE2, are not functional alternatives (Boshoff et al., 2003). DnaE1 
provides replicative polymerase activity and DnaE2 is part of the SOS response in M. 
tuberculosis (Tippin et al., 2004). The involvement of a C-family polymerase in a bacterial 
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DNA damage response was novel and defined a characteristic feature of the SOS response 
operating in M. tuberculosis and M. smegmatis (Boshoff et al., 2003; Kana et al., 2010; 
Smollett et al., 2012; Warner et al., 2010). Subsequent to the study by Boshoff et al. (2003) 
several other groups identified an association between DnaE2-type C-family DNA 
polymerases and two other proteins, termed ImuA (for inducible mutagenesis) and ImuB 
(Abella et al., 2004; Erill et al., 2006; Galhardo et al., 2005). In particular, these authors 
observed that bacterial genomes containing a DnaE2-type DNA polymerase always encode 
an ImuB orthologue (Figure 1) and, further, that the ImuA-ImuB-DnaE2 triad – often present 
in these genomes as an SOS-inducible gene cassette – might represent the functional 
equivalent of the mutagenic DNA polymerase V (encoded by umuDC), most well 
characterised in E. coli (Galhardo et al., 2005; Koorits et al., 2007). Included with dnaE2 in 
the mycobacterial SOS response is an operon encoding a protein of unknown function, 
Rv3395c, and its partner, Rv3394c (Figure 1). The interesting feature of Rv3395c is that its 
orthologues are limited to Actinobacterial genomes including M. tuberculosis. Because 
Rv3394c, Rv3395c and DnaE2 are DNA damage induced, it suggests that they might 
function in the same pathway. 
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Figure 1: An SOS-inducible mutagenic gene cassette. The M. tuberculosis genome encodes 
principal components of a DNA damage-inducible cassette, DnaE2 and Rv3394c, separated by ~25kb. 
Orthologues of Rv3395c are found only in Actinobacterial genomes. 
Rv3394c was designated the founder member of the DinB3 subfamily of Y-polymerases 
because of its predicted β-binding motif (Dalrymple et al., 2003). The β-clamp modulates the 
recruitment to the replication fork of many proteins involved in various steps of DNA 
replication, recombination, and repair, with the current model holding that these processivity 
factors function as molecular “tool-belts” (Pages & Fuchs, 2002) to attach replicative and 
TLS polymerases to the primer-template junction interchangeably without disruption of the 
core assembly. It has been shown by bioinformatic analysis that DnaE2 does not have a β-
binding motif and Tippin et al (2004) suggested that DnaE2 may require other proteins in 
order to access the replication fork. The absence of an identifiable β-clamp binding motif in 
DnaE2 poses an important question as to how it accesses the replication fork.   
1.8 Working hypothesis 
Previous work from the MMRU identified the DNA damage-inducible C-family DNA 
polymerase, DnaE2, and which was subsequently implicated in virulence and the emergence 
of rifampicin in M. tuberculosis in vivo (Boshoff et al., 2003). However, a fundamental 
question at the time pertained to the ability of DnaE2 to access the DNA replication fork 
given the apparent absence of a predicted clamp binding motif in the mutagenic polymerase. 
Therefore, the failure to identify a putative β-binding motif suggested the operation of a novel 
mutagenic mechanism. Subsequently, the two hypothetical proteins, Rv3394c (ImuB) and 
Rv3395c (ImuA’) were shown to function as essential accessory factors in DnaE2-mediated 
mutagenesis. Specifically, disruption of either gene eliminates damage-induced mutagenesis, 
and rendered the mutant strains hypersensitive to DNA damaging agents, thereby 
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recapitulating precisely the dnaE2 deletion phenotype. Rv3395c encodes a protein of 
unknown function restricted to Actinomycetes; in contrast, Rv3394c is an orthologue of 
ImuB-type proteins (implicated in DNA repair and mutagenesis in other organisms) and, like 
ImuB, possesses a predicted β-clamp binding motif. This is significant since it raises the 
possibility that Rv3394c might function as molecular adaptor, directly mediating the 
interaction of DnaE2 with template DNA. These data established a working model in which 
all three proteins – Rv3394c, Rv3395c and DnaE2 – must interact in order for DnaE2 to 
access the replication fork. However, the nature of this interaction, as well as the specific 
residues required for interaction were unknown, but would be critical to the design of novel 
compounds to disrupt complex formation. 
1.9 Aims and Objectives 
The aim of this study was to define key functional and structural characteristics of the 
replication complex responsible for DNA damage-induced mutagenesis in M. tuberculosis. 
To achieve the aim the following objectives were pursued: 
 To elucidate, by targeted (genetic) disruption of protein-binding domains, the 
functional interactions that are essential for DnaE2-dependent mutagenesis; 
 To identify other proteins involved in DnaE2-dependent mutagenesis 
 To express and purify sufficient quantities of ImuB and ImuA’ protein to enable 
subsequent crystallization and structural analysis. 
 To use proteomics as a tool to examine  the role of DnaE2 in other pathways 
under conditions of normal growth or genotoxic stress conditions 
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Chapter 2 
2. Materials and Methods 
All general procedures and DNA manipulations were performed according to standard 
protocols (Sambrook, 2001; Sambrook, 1989). All culturing and molecular biological 
manipulations of mycobacterial were performed according to published methods (Larsen, 
2000; Parish & Stoker, 2000; Snapper et al., 1990). The composition of culture media and 
solutions are detailed in the Appendix.  
2.1. Bacterial strains, plasmids and culture conditions 
All bacterial strains and cloning vectors used in this study are listed in Tables 2.1 and 2.2. 
Glycerol stocks of bacterial strains were prepared in 33.3% glycerol (V/V) and stored at -
70°C.  
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         Table 2.1: Strains used in the study  
Strain Description Reference/ 
Source 
Yeast   
AH109 HIS3, ADE2, lacZ, MEL1 containing reporter genes for screening 
protein interactions 
Clontech 
M. smegmatis   
mc2155 High frequency transformation mutant of M. smegmatis mc26;  ATCC        
706 
(Snapper et al., 
1990) 
∆dnaE2::aph dnaE2 knockout mutant of mc2155; KmR (Boshoff et al., 
2003) 
∆dnaE2::aph attB::dnaE2 dnaE2::aph complemented with dnaE2 at attB site; KmRHygR (Boshoff et al., 
2003) 
∆imuA’ imuA’ deletion mutant of mc2155 (Warner et al., 
2010) 
∆imuA attB’::imuA’ ∆imuA’ complemented with full-length imuA’ at attB site; KmR (Warner et al., 
2010) 
∆imuA attB’::imuAN3XFLAG ∆imuA’ complemented with imuAN3XFLAG allele at attB site; KmR This study 
∆imuB imuB deletion mutant of mc2155 (Warner et al., 
2010) 
∆imuB attB’::imuB ∆imuB complemented with full-length imuB at attB site; KmR (Warner et al., 
2010) 
∆imuB attB’::imuBN3XFLAG ∆imuB complemented with imuBN3XFLAG allele at attB site; KmR This study 
∆imuA’-imuB imuA’-imuB double knockout mutant of mc2155 (Warner et al., 
2010) 
∆imuA’-imuB attB’::imuA’-imuB ∆imuA-’imuB complemented with full-length imuA’-imuB at attB site; 
KmR 
(Warner et al., 
2010) 
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∆imuA’-imuB attB’::imuA’-
imuBC168 
∆imuA-’imuB complemented with imuA’-imuBC168 allele at attB site; 
KmR 
(Warner et al., 
2010) 
∆imuA’-imuB attB’::imuA’-imuBCHis-
FLAG
 
∆imiA’-imuB complemented with imuA’-imuBCHis-FLAG allele at attB site; 
KmR 
Dr. D. Warner 
E. coli   
DH5α E. coli strain used for transformation and propagation of plasmids Laboratory stock 
BL21 (DE3) E. coli strain used for heterologous expression of M. tuberculosis 
proteins.  
Laboratory stock 
 
Table 2.2: Plasmids used in the study  
Plasmid Description Source 
pAINT E. coli–Mycobacterium integrating shuttle vector; KmR,ApR Laboratory 
stock 
pAMSIMUA M. smegmatis imuA′ complementation vector – pAINT carrying full-length M. smegmatis 
imuA′; KmR 
Dr. D. Warner 
pAMSIMUAB M. smegmatis imuA′-imuB complementation vector – pMC1r carrying full-length M. 
smegmatis imuA’-imuB, KmR 
Dr. D. Warner 
pAINT1620stop 1 M. smegmatis imuA′ complementation vector – pAINT carrying containing truncated imuA′∆C; 
KmR 
This study 
pGADT7  Y2H vector to produce AD fusions, GAL4(768-881) AD, LEU2, HA epitope tag; ApR Clontech 
pGBKT7  Y2H vector to produce BD fusions, GAL4(1-147) DNA-BD, TRP1, c-MYC epitope tag; KmR Clontech 
pGADDnaE1  pGADT7 containing M. tuberculosis dnaE1 ORF fused to GAL4 AD,  ApR Dr. G. 
Abrahams  
pGADDnaE2  pGADT7 containing M. tuberculosis dnaE2 ORF fused to GAL4 AD, ApR Dr. G. 
Abrahams  
pGADDnaN pGADT7 containing M. tuberculosis dnaN ORF fused to GAL4 AD, ApR Dr. G. 
Abrahams  
pGADImuA′ pGADT7 containing M. tuberculosis imuA′ ORF fused to GAL4 AD, ApR  Dr. G. 
Abrahams  
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pGADImuB pGADT7 containing M. tuberculosis imuB ORF fused to GAL4 AD, ApR  Dr. G. 
Abrahams  
pGADImuB stop1  pGADT7 containing ImuB with 168 amino acids truncated on the C-terminus fused to GAL4 
AD, ApR  
This study 
pGADImuBstop 2 pGADT7 containing ImuB C-terminally truncated from the β-clamp binding motif fused to 
GAL4 AD, ApR 
This study 
pGADImuBstop 3 pGADT7 containing ImuB C-terminally truncated from the little finger domain fused to GAL4 
AD, ApR 
This study 
pGADImuBstop 4 pGADT7 containing ImuB C-terminally truncated from the thumb domain fused to GAL4 AD, 
ApR 
This study 
pGADImuBstop 5 pGADT7 containing ImuB C-terminally truncated from the thumb domain fused to GAL4 AD, 
ApR 
This study 
pGADImuBstart 1 pGADT7 containing the C-terminal region of ImuB fused to GAL4 AD, ApR This study 
pGBDImuA’ pGBKT7 containing M. tuberculosis ImuA’ ORF fused to GAL4 BD, KmR Dr. G. 
Abrahams  
pGBDImuA’ start1 pGBKT7 containing ImuA’ truncated on the N-terminal domain ORF fused to GAL4 BD, KmR This study 
pGBDImuA’ start2 pGBKT7 containing ImuA’ truncated on the N-terminal domain ORF fused to GAL4 BD, KmR This study 
pGBDImuA’ pGBKT7 containing C-terminally truncated truncated ImuA’ fused to GAL4 BD, KmR This study 
pMalc2 E. coli expression vector containing maltose binding protein tag; ApR New England 
Biolabs 
pMal13 pMalc2 containing full-length M. tuberculosis ImuB N-terminally fused to Maltose binding 
protein tag, ApR 
This study 
pMal14 pMalc2 containing full-length M. tuberculosis ImuA’ N-terminally fused to Maltose binding 
protein 
This study 
pMal13stop 1 pMalc2 containing C-terminally truncated  ImuB N-terminally fused to Maltose binding 
protein, ApR 
This study 
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2.1.1 Bacterial growth conditions 
Escherichia coli strains 
E. coli cells containing plasmids were grown in Luria-Bertani (LB) broth supplemented with 
appropriate selective agent at 37°C overnight, with vigorous shaking (Labcon Shaking 
Incubator) or at 30°C in a New Brunswick Scientific Innova 400 shaker. For selection on 
solid media, E. coli strains containing plasmids were grown on Luria-Bertani agar (LA) 
containing appropriate selective agent at 37°C overnight in an Incotherm Labotec Incubator 
or 48 h at 30°C in a Heraeus Instrument Incubator. E. coli cells carrying plasmids greater than 
8 kb in size were grown at 30°C standing to limit plasmid rearrangement.  
Selection agents used for strains carrying plasmids were as follows: 100 µg/ml ampicillin 
(Ap), 200 µg/ml hygromycin (Hyg), and 50 µg/ml kanamycin (Km). For confirmation of 
disruption of the lacZα cassette during cloning or identification of a clone containing the 
lacZα cassette, 40 µg/ml of 5-bromo-4-chloro-3-indolyl-β-galactoside (X-gal) and 4µg/ml of 
its substrate isopropyl-β-D-thiogalactopyranoside (IPTG) were added to the growth medium. 
Mycobacterial strains 
Unless otherwise indicated, M. smegmatis strains were grown in Middlebrook 7H9 medium 
supplemented with 0.05% Tween 80 or on Middlebrook 7H10 solid medium both 
supplemented with glucose salt (0.085% NaCl, 0.2% glucose) and 0.5% glycerol.  
The selection agents used for strains carrying plasmids were as follows: 50 µg/ml Hyg and 20 
µg/ml Km. Resistant mutants were selected on Middlebrook 7H10 solid medium 
supplemented with Oleate-albumin-dextrose-catalase (OADC), 0.5% glycerol and rifampicin 
(Rif) 200 µg/ml.  
Yeast strains 
Saccharomyces cerevisiae strains, unless otherwise stated, were grown in rich YPD broth 
(0.1% Yeast extract, 0.2% Peptone and 0.2% Glucose) or on YPD agar (0.15% agar) both 
supplemented with 0.003% adenine. 
Selection of strains carrying plasmids was on minimal synthetic drop-out (SD) media with 
leucine and tryptophan excluded. Drop-out medium (0.67 % Yeast nitrogen base without 
amino acids, 2 % Glucose, 2 % Bacto agar and 0.02 % drop-out mix) is used for the selection  
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of plasmids based on the use of auxotrophic mutant strains which cannot grow without a 
specific media component.  Transformation with a plasmid containing the gene required for 
growth in the absence of the specific component enables the transformant to grow on a 
medium lacking the required component, allowing for selection.  
2.2 General DNA manipulations  
2.2.1 DNA Extraction 
E. coli mini plasmid preparation 
An individual bacterial colony was inoculated into 1 ml of LB containing the appropriate 
selective agent in a 2-ml Eppendorf tube, which was incubated at 37°C with agitation 
overnight. The cells were harvested by centrifugation at room temperature for 1 min. The 
supernatant was decanted and the pellet re-suspended in 80 µl of Solution I (50 mM glucose, 
25 mM Tris hydrochloride, 10 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0) by 
vortexing. Then, 160µl of Solution II (0.2 M sodium hydroxide, 1% Sodium dodecyl sulphate 
(SDS)) was added to the cell suspension and mixed by gentle inversion of the tube. 
Thereafter, 120 µl of Solution III (5M potassium acetate, 11.5 % glacial acetic acid) was 
added and the mixture shaken vigorously and centrifuged (13200 rpm; 16 100 xg) at room 
temperature for 10 min to remove cellular debris. The supernatant was collected into a new 
sterile Eppendorf tube and isopropanol (220 µl) was added. The precipitation process was 
allowed to continue at room temperature for 5 min before the DNA was harvested by 
centrifugation at a speed of 13200 rpm at room temperature for 10 min. The pellet was 
washed with 150 µl ethanol and vacuum-dried for 20 min (SpeedVac, Savant, Farmingdale, 
NY, USA). The DNA was then re-suspended in 50 µl of sterile distilled water containing 
freshly boiled ribonuclease (RNase) (1 µl of 10 mg/ml). A small aliquot was analyzed on an 
agarose gel.  
E. coli bulk plasmid preparation 
A single colony was used to inoculate 100 ml of LB supplemented with the appropriate 
selective agent for maintenance of the plasmid. The culture was grown with gentle agitation 
at 37°C for overnight. The cells were transferred into two 50-ml Falcon tubes and harvested 
by centrifugation at 4500 rpm (3900 × g) in a Beckman Coutler Allegra X-22 (4250 rotor) 
centrifuge for 10 min. The cell pellets were resuspended in 1 ml of Solution I and to the 
suspension, 2 ml of Solution II was added followed by gently inverting the tubes for mixing.  
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To the mixture, 1.5 ml of Solution III was added and shaken vigorously and then 900 µl 
aliquots transferred into ten 1.5-ml Eppendorf tubes. Cell debris was removed by 
centrifugation at 13200 rpm (16 100 × g) in an Eppendorf Centrifuge 5415 D with standard 
rotor F-45-24-11(Eppendorf, Hamburg, Germany) for 10 min. The supernatant was 
transferred to a fresh, sterile 1.5 ml Eppendorf tube and 3 µl RNaseA (10 mg/ml stock) was 
added to each tube, followed by incubation at 42°C for 1 h. To each tube, 700 µl of 
isopropanol was added followed by centrifugation for 10 min at 13200 rpm at room 
temperature to precipitate the DNA. The supernatant was decanted and the DNA pellet 
washed with 500 µl of ice-cold 70 % ethanol. The DNA from each tube was resuspended in 
100 µl sterile distilled water (sdH2O) and the DNA from five tubes pooled together to a 
volume of 500 µl to which was added 50 µl of 5.3 M sodium chloride (pH 5.2) and 700 µl of 
phenol:chloroform (1:1). The mixture was centrifuged at room temperature for 10 min at 
13200 rpm and the top aqueous layer transferred into a clean Eppendorf tube. A volume of 
350 µl of chloroform:isoamyl alcohol (24:1) was added to the aqueous solution and the 
mixture centrifuged for 10 min at room temperature. The aqueous layer was transferred to a 
clean Eppendorf tube to which was added 1 ml of ice-cold 100 % ethanol. The tube was 
inverted for mixing and kept at -20°C for 30 min to 24 h before centrifugation at room 
temperature for 25 min. DNA pellet was washed with 70% ethanol and vacuum-dried with a 
Speed-Vac. The DNA was resuspended in 50-200 µl of sdH2O and quantified using a 
NanoDrop ND-1000 Spectrophotometer (Thermo Scientific) according to the manufacturer’s 
instructions. 
Chromosomal DNA extraction from mycobacteria 
Mycobacterial chromosomal DNA was isolated using a modified cetyltrimethylammonium 
bromide (CTAB; ICN Biomedicals, Aurora, Ohio) method (Larsen, 2000; Warner et al., 
2010). Briefly, mycobacterial cells were harvested and re-suspended in 500 µl of TE buffer 
(10 mM Tris hydrochloride pH 8.0; 1 mM EDTA). The cells were heat-killed at 65°C for 10 
min for M. smegmatis, harvested by centrifugation (13200 rpm (16 100 × g) for 5 min and re-
suspended in 500 µl of TE buffer. To this was added 50 µl lysozyme (10 mg/ml) and the 
reaction incubated at 37°C overnight. 70µl 10 % SDS and 6 µl of proteinase K (10 mg/ml) 
was then added and the mixture incubated at 65°C for 2 h. 100 µl of a 5 M solution of sodium 
chloride and 80 µl of pre-warmed CTAB/NaCl mix (10 % CTAB made in 0.7 M sodium 
chloride) was added to the sample and incubated at 65°C for a further 10 min. An equal  
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volume of chloroform:isoamyl alcohol (24:1) was added to remove residual proteins. 
Subsequent to centrifugation (13200 rpm for 10 min) the aqueous phase containing the DNA 
was precipitated by addition of 1/10 × volume of 5.3M sodium acetate (pH 5.2) and 2.5 × 
volumes of 100 % ethanol, and incubation at -20°C for 1 h. The DNA was then pelleted by 
centrifugation (13200 rpm for 20 min), washed with ice-cold 70% ethanol, dried in a vacuum 
centrifuge and resuspended in sdH2O. 
2.2.2 DNA manipulations 
Restriction enzyme digestion 
Enzymes were obtained from Fermentas, Boehringer Mannheim, New England Biolabs 
(NEB), Amersham or Roche Applied Science and used according to manufacturer’s 
instructions. Plasmid DNA of up to 5 µg was digested in a 20 µl reaction volume for 1-24 h. 
Digested samples were incubated at the recommended temperature for maximal enzyme 
activity for at least 4 h. For double digestions, an appropriate buffer in which both restriction 
enzymes showed suitable activity was selected, otherwise the digestions were performed 
sequentially starting with the enzyme that require the lower pH buffer. DNA fragments were 
then separated on agarose gels by electrophoresis (See section 2.2.3). 
Phoshorylation of DNA  
Phosphorylation of blunt-ended PCR products to enable ligation with de-phosphorylated 
vector was performed for 30 min at 37°C using polynucleotide kinase (Roche Applied 
Science), as per the manufacturer’s instruction.  Reactions were stopped by separation on an 
agarose gel. 
Dephosphorylation of 5’ ends of plasmid DNA 
Following plasmid digestion, the 5’-phosphate of linearized vector DNA was removed by 
treatment with Antarctic Alkaline Phosphatase (New England Biolabs) to prevent vector re-
ligation. Dephosphorylation reactions were carried out for 1-12 h at 37°C, after which the 
enzyme was heat inactivated for 20 min at 65°C. The DNA was cleaned by using the 
Nucleospin kit (Macherey-Nagel) as per manufacturer’s instructions. Briefly, the de-
phosphorylated DNA was loaded onto a Nucleospin column, and washed. The DNA was then 
eluted using pre-warmed sdH2O. The DNA was quantified either on agarose gels by  
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comparison to DNA molecular weight markers or using a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). 
Ligation reactions 
DNA ligations were performed using either the Fast-LinkTM ligation kit (Epicentre® 
Biotechnologies) or T4 DNA Ligase (Roche Applied Science), as per instructions from the 
manufacturer. The ligation reactions were then used for transformation into E. coli DH5α 
cells (See section 2.2.5). 
2.2.3 Agarose gel electrophoresis 
Standard gel electrophoretic techniques were used to separate DNA fragments (Sambrook, 
1989). For the separation of high molecular weight DNA fragments, 0.8 -1 % agarose gels, 
prepared in 1×TAE buffer (1 mM EDTA, 40 mM Tris-acetic acid, pH 8.5) were used. For 
low molecular weight DNA fragments of ≤1kb, 2 % agarose gels were used. All gels 
contained 0.5 µg/ml ethidium bromide and the DNA samples were loaded with a tracking dye 
(0.025 % bromophenol blue in 30% glycerol). Lambda DNA molecular weight markers (III, 
IV and V; Roche Applied Science) were used to assess DNA fragment sizes. The agarose 
gels were electrophoresed between 80 – 100 V in a Mini-Sub Cell GT mini-gel horizontal 
submarine unit (Bio-Rad) and visualized under UV-light using the G:Box (Syngene) gel 
documentation system. 
2.2.4 DNA fragment recovery from agarose gels and quantification 
The required DNA fragment was excised from the gel and purified using the Nucleospin kit 
(Macherey-Nagel) as per manufacturer’s instructions. Briefly, the excised gel fragment was 
melted in a binding buffer by incubation at 60˚C and loaded onto a Nucleospin column, and 
washed. The DNA was then eluted using pre-warmed sdH2O. The DNA was quantified either 
on agarose gels by comparison to DNA molecular weight markers or using a NanoDrop ND-
1000 Spectrophotometer (Thermo Scientific). 
2.2.5 Transformation of bacteria 
Chemical transformation of E. coli 
Chemically competent E. coli DH5α cells were used for transformation of plasmids. The cells 
were prepared by rubidium chloride treatment, as follows. A 1-ml aliquot of a stationary 
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phase overnight culture was inoculated in 100 ml of LB and grown to an OD600 of 0.48 - 
0.55. The cells were chilled on ice for 15 min and harvested by centrifugation at 4500 rpm 
(3900 × g) for 5 min at 4°C). The pellets were re-suspended in 20 ml of transformation buffer 
(Tfb) I solution (30 mM potassium acetate; 100 mM rubidium chloride; 10 mM calcium 
chloride; 50 mM manganese chloride; 15% v/v glycerol; pH 5.8), and chilled on ice for 15 
min. The cells were harvested by centrifugation at 4500 rpm  for 5 min at 4°C), re-suspended 
in 2 ml Tfb II solution (10 mM MOPS; 75 mM calcium chloride; 10 mM rubidium chloride; 
15 %  glycerol; pH 6.5) and 500 µl aliquots were flash-frozen in ethanol and stored at -80°C 
until further use. 
For transformations, E. coli DH5α competent cells were thawed on ice and 100 µl of cells 
used per transformation. Up to 1µg of plasmid DNA was incubated with the cells on ice for 
1h, heat-shocked for 90 s at 42°C and chilled on ice for 2 min. Four volumes of 2×TY (0.16 
% Bactotryptone, 0.10 % Bacto yeast extract and 0.05% sodium chloride) medium was added 
to rescue the cells at 37°C for 1 h. These were plated on LA media containing the appropriate 
antibiotics, and incubated for 1 - 2 days at 37°C. 
Electroporation into Mycobacterium smegmatis 
M. smegmatis electroporations were carried out as previously described (Larsen, 2000). 
Briefly, 1 ml of a stationary-phase M. smegmatis culture was inoculated in 100 ml of LB 
containing 0.05% Tween 80 and grown to an OD600 of 0.4 - 0.7. The cells were harvested by 
centrifugation at 3500 rpm (2000 × g) for 10 min at 4°C) and the pellet washed three times by 
gentle re-suspension in 10 ml of ice-cold 10% glycerol before collection by centrifugation at 
3500 rpm for 10 min at 4°C. The pellet was re-suspended in 1 ml of ice-cold 10% glycerol 
and cells used immediately. Up to 5 µg of plasmid DNA was added to 400 µl M. smegmatis 
competent cells. The mixture was transferred to a 0.2 cm electroporation cuvette and pulsed 
using the following settings: 2.5 kV, 25 µF and 1000 Ω. The cells were rescued immediately 
with 1 ml of 2×TY for at least 5 h at 37°C before plating on Middlebrook 7H10 media 
supplemented with appropriate antibiotics. The plates were and incubated for 3 - 7 days at 
37°C before scoring CFUs.  
Lithium acetate-mediated yeast transformation 
A single colony from YPD agar plate or freezer stock was inoculated into YPD broth and 
vigorously vortexed to disperse the clumps followed by incubated at 30˚C with shaking for 
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48 h. 1 ml of the culture was inoculated into 50 ml YPD broth and incubated at 30˚C for 16–
18 h with shaking at 250 rpm until the culture reached stationary phase (OD600 > 1.5). A 30-
ml aliquot of the culture was transferred to a flask containing 300 ml YPD broth and the 
resulting culture (OD600 =0.2-0.3) was incubated at 30˚C with shaking for 3 h to reach an 
OD600 of 0.4-0.6. Cells were transferred into six 50-ml tubes and centrifuged at 2278 rpm 
(1000 × g) for 5 min at room temperature. The supernatant was discarded and the pellets in 
each tube re-suspended in 25 ml sdH2O. The re-suspended cells were pooled into three 50-ml 
tubes to a final volume of 50 ml and centrifuged at 1000 × g for 5 min at room temperature. 
The supernatant was decanted and pellets re-suspended in 1.5 ml freshly prepared, sterile 
1×TE/1×LiAc solution (10 mM Tris-hydrochloride, 1 mM EDTA, pH 8.0 plus 0.1 M lithium 
acetate, pH 7.5). 
Plasmid DNA (0.1 µg) and 0.1 mg of herring testes carrier DNA (Invitrogen) were added to a 
fresh 1.5 ml tube and mixed thoroughly. 100µl of competent yeast cells were added to the 
tube containing DNA and the sample was mixed by vortexing. To this tube, 600 µl of sterile 
PEG/LiAc solution (40% Polyethylene glycol 3350, 10 mM Tris-hydrochloride, 1 mM 
EDTA, pH 8.0 plus 0.1 M lithium acetate, pH 7.5) was added and mixed by vortexing at high 
speed for 10 sec followed by incubation at 30°C for 30 min with shaking at 200 rpm. Seventy 
µl of dimethyl sulfoxide (DMSO) was added and mixed by gently inversion and the 
suspension was heat-shocked for 15 min at 42˚C then chilled on ice for 1-2 min. The cells 
were centrifuged for 5 s at 13200 rpm (16 100 × g) at room temperature and 500 µl TE buffer 
(10 mM Tris-hydrochloride, 1 mM EDTA, pH 8.0) was added once the supernatant was 
removed. The suspension was plated on synthetic drop-out (SD) agar to select for the desired 
transformants and the plates incubated at 30˚C for 3-5 days. 
2.2.6 Polymerase Chain Reaction (PCR) 
All preliminary and screening PCRs were performed using the Roche FastStart kit (Roche 
Applied Science), while for the amplification of fragments required for cloning, Phusion 
High-Fidelity DNA polymerase (Finnzymes) was used. The reactions were performed as per 
the manufacturer’s instructions. For reactions using the Roche FastStart Taq DNA 
polymerase, 20-50 µl reactions were set up containing: 1× reaction buffer, up to 50 ng 
plasmid or 200 ng genomic DNA (gDNA), 200 µM of each dNTP, 0.5-1.0 µM of each 
primer, 1.5 mM magnesium chloride, 1× GC-rich solution and 2U per 50 µl reaction of the 
DNA polymerase. DNA amplification was performed using the following cycling 
32 
 
parameters: denaturation at 94°C for 5 min; followed by 30 cycles of denaturation at 94°C for 
60s, annealing for 30 s at 60˚C and extension at 72°C for 60 s; with a final extension at 72°C 
for 7 min. For reactions using the Phusion High-Fidelity DNA polymerase (Finnzymes), 20–
50 µl reactions were set up to contain: 1× reaction buffer, up to 50 ng plasmid or 200 ng 
genomic DNA (gDNA), 200 µM each dNTP, 0.5 µM each primer, 3% DMSO and 0.02 U/µl 
of the DNA polymerase. DNA amplification was then performed using the following cycling 
parameters: denaturation at 98°C for 30 s; followed by 25-35 cycles of denaturation at 98°C 
for 10 s, annealing for 30 s, and extension at 72°C for 30 s/kb; with a final extension at 72°C 
for 7 min. For each amplification reaction, three control reactions (a no DNA control 
reaction; a reaction containing only the forward primer and another containing only the 
reverse primer) were used to elucidate the presence of genomic contamination and/or non-
specific DNA amplification if present. All PCRs were performed using a MyCyclerTM 
thermal cycler (Bio-Rad) with oligonucleotide primers obtained from Inqaba Biotech Ltd. 
2.2.7 DNA Sequencing 
DNA sequencing was outsourced to either Inqaba Biotech Ltd (South Africa) or the Central 
Analytical Facilities-DNA Sequencing Unit of Stellenbosch University, and was performed 
using the Big Dye terminator v3.1 Cycle Sequencing kit and Bioline Half Dye Mix. The 
EditSeq and SeqManTM modules of the Lasergene 99 suite of software (DNASTAR, Inc., 
Madison, Wisconsin, USA.) were used to analyse the sequencing data. 
2.3 Construction of vectors for interaction studies 
2.3.1 Construction of vectors for yeast two hybrid system 
Genes of interest were cloned in-fusion with activator (AD) and binding (BD) domains of the 
GAL4 transcription regulator (Kana et al., 2010; Warner et al., 2010). Artificial start and stop 
codons were introduced into imuB and imuA’ to generate truncated proteins on the N- or C-
terminus, respectively.  
For imuB, primers in Table 2.3 were used to PCR amplify the truncated versions using 
pGADImuB as a template. The resulting PCR products contained 5’ NdeI and 3’ EcoRI 
restriction sites for cloning into pGADT7. For imuA’, primers in Table 2.3 were used to 
amplify the truncated version using pGBKImuA’ as a PCR template and resulting PCR 
products cloned into pGBKT7 using the flanking 5’ NdeI and 3’ EcoRI restriction sites, 
respectively. Correct clones were confirmed by restriction analysis and sequencing.   
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Table 2.3: Primers used to introduce artificial start and stop codons into the ImuB and 
ImuA’ ORFsa 
Primer Name Primer sequence 
ImuB-NdeI-Forward 
 
ImuB-EcoRI-Reverse 
 
ImuB-Start-1-forward 
 
ImuB-Stop-1-Reverse 
 
ImuB-Stop-2-Reverse 
 
ImuB-Stop-3-Reverse 
 
ImuB-Stop-4-Reverse 
 
ImuB-Stop-5-Reverse 
 
ImuA’-NdeI-Forward 
 
ImuA’-EcoRI-Reverse 
 
ImuA’-Start1-Forward 
 
ImuA’-Start 2-Forward 
 
ImuA’-Stop 1-Reverse 
5’-ATAAAACATATGATGGCCTCCGCTCGC-3’ 
 
5’-ATAGAATTCTCATTCGTAGCTTCCCAC-3’ 
 
5’-ATAAAACATATGATGCTCGGTGAACAGGACAGG  CTT-3’ 
 
5’-ATAGAATTCTCAGCCCCATAGCGGCAACTGCAAGCCT-3’ 
 
5’-ATAGAATTCTCACGATGCGGACACCGTCTCCACCGCCT-3’ 
 
5’-ATAGAATTCTCATTCCGGTTCGCCGCGGGCGAACCG-3’ 
 
5’-ATAGAATTCTCATCGGCTCGGTGGCAAGTTGGCGGA-3’ 
 
5’- ATAGAATTCTCACGACAGAAACCGCGCATCGCCT-3’  
 
5’-ATAAAACATATGACTGCGGCCTTCGCCT-3’ 
 
5’-ATAGAATTCTCACCGTCCACGCCCGTT-3’ 
 
5’-ATAAAACATATGTCCGGGGGGCCCAGC-3’ 
 
5’-ATAAAACATATGTTCCCCCCGGGGGACGGTG-3’ 
 
5’-ATAGAATTCTCAGCCGTCGGTGACCAGCA-3’ 
 
aRestriction sites are underlined. 
 
2.3.2 Construction of vectors expressing tagged proteins for pull-down assay 
Incorporation of a Tandem Affinity Purification (TAP) tag into MsImuB  
MsImuB was C-terminally tagged with a His-FLAG TAP tag by Dr. Digby Warner. Briefly, 
a His-FLAG tag was introduced in the 3’ end of imuB followed by a stop codon which was 
carried in pAINTPCRcomp  plasmid to enable cloning of the upstream region containing the 
SOS box and the gene encoding MsImuA’ into the complementing vector, pMCpAINT.   
Incorporation of 3×FLAG sequence onto the N-terminus of MsImuB  
The gene encoding MsImuB protein was PCR amplified from plasmid pAMSIMUAB using 
the primers listed in Table 2.2. The FLAG sequence was incorporated at the 5’-end of the 
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gene by nested PCR. Briefly, the first round of PCR was performed using primers 
3xflag1622F1 and 1622R to incorporate half of the FLAG sequence on the 5’ end and an 
Acc65I restriction site at the 3’ end of MSMEG_1622, resulting in a PCR product of 1605 bp. 
The PCR product from the first round was used as a template with primers 3xflag1622F2 and 
1622R to incorporate the entire sequence of the FLAG tag, including the start codon, and 
resulting in an amplicon of 1650 bp. An upstream region of 770 bp which includes the SOS 
box was amplified from plasmid pAINTPCRcomp using the primers 1620F1Acc65I and 
1620R, with the forward primer incorporating an Acc65I restriction site. The PCR products 
were digested with Acc65I and ligated into pAINT on the same restriction site. Correct clones 
were screened by restriction digestion with Acc65I. Only the clones that gave an insert of 
2375 bp were chosen for further restriction analysis and sequencing to confirm that the 
Methionine-3× FLAG sequence was correctly fused on the 5’ end of imuB gene.  
Table 2.4: Incorporation of a 3xFLAG sequence on the N-terminus of MsImuA’ 
MsImuBa 
Primer Name Primer sequence 
1620F1Acc65I 
 
1620R 
 
1622R 
 
3x flag1622F1 
 
 
3x flag1622F2 
 
 
3x flag 1620F1 
 
 
3x flag 1620F2 
 
 
1620R 
 
1620FAcc65I 
5’- ATAGGTACCTCGAGCAATCGAACATACAT-3’ 
 
5’-GTCTAACCGCCCACCGCACGT-3’ 
 
5’-ATAAAAGGTACCTCACTCATAGGCACC-3’ 
 
5’-GATAAAGATTATAAGGATGACGACGATAAACCCGAGGGTT 
CCCGGGTGCT-3’ 
 
5’- ATGGATTATAAGGATGACGACGATAAAGATTATAAGGAT 
GACGACGATAAAGATTATAAGGATGA-3’ 
 
5’-ACGACGATAAAGATTATAAGGATGACGACGATAAACCCAC 
AGCTGCGGCTGACCTTGATG-3’ 
 
5’-ATGGATTATAAGGATGACGACGATAAAGATTATAAGGATGA 
CGACGATAAAGATTATAAG-3’ 
 
5’-ATAGGTACCGTCTAACCGCCCACCGCACGT-3’ 
 
5’-ATAGGTACCGCTTCAGGTCAGAGGTTTCG-3’ 
 
aRestriction site underlined 
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Incorporation of 3×FLAG sequence onto the N-terminus of MsImuA’  
The full-length imuA’ gene together with the upstream region that incorporates the SOS box 
was PCR amplified from plasmid pAINTPCRcomp using the oligonucleotides listed in Table 
2.4. The FLAG sequence was incorporated at the 5’-end of the genes by nested PCR. Briefly, 
the first round of PCR was performed using primers 3xflag1620F1 and 1620R to incorporate 
half of the FLAG sequence on the 5’ end and an Acc65I restriction site at the 3’ end of imuA’ 
gene resulting in PCR product of 744 bp. The PCR product from the first round was used as a 
template with primers 3xflag1620F2 and 1620R to incorporate the entire sequence of the 
FLAG-tag including the start codon resulting in an amplicon of 784 bp. An upstream region 
of 770 bp which includes the SOS box was amplified from pAINTPCRcomp using the 
primers 1620F1Acc65I and 1620R, with the forward primer incorporating an Acc65I 
restriction site. The PCR products were digested with Acc65I and inserted into the Acc65I site 
in pAINT. Correct clones were screened by restriction digestion with Acc65I. Only the clones 
that gave an insert of 1554 bp were chosen for further restriction analysis and sequencing to 
confirm that the 3×FLAG sequence was fused with the gene. 
2.3.3 Construction of complementing vectors expressing truncated MsImuA’  
An artificial stop codon was introduced intoMsImuA’ at amino acid position 480 to truncate 
the C-terminal unstructured region. PCR was employed using primers 1620FAcc65I (5’-
ataggtaccgcttcaggtcagaggtttcg-3’) and 1620Stop1Aps718IR (5’-
ataggtaccctacccgtcggtcaccag-3’) with restriction sites in bold and pAINTPCRcomp plasmid 
(Table 2.2) as a template. The PCR product was then digested with Acc65I (or the 
isoschizomer, Asp718I) and cloned in the Acc65I site of the pAINT vector. Clones were 
confirmed by restriction analysis and sequencing.  
2.3.4 Construction of complementing vectors expressing truncated MsImuB  
A C-terminally truncated version of ImuB was generated by Dr. D. Warner in a PCR reaction 
that effectively removed the 168 amino acid C-terminal region immediately after the 
predicted β-clamp binding motif. The truncated allele was cloned into the complementing 
vector, pMCpAINT (Warner et al., 2010). 
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2.4 Construction of vectors for protein expression 
Escherichia coli expression vectors 
The imuB and imuA’ open reading frames were PCR amplified from plasmid DNA 
(pGADImuB and pGADImuA’) using the oligonucleotides listed in Table 2.5 The ORFs 
were cloned into the EcoRI site of the expression vector pMalc2. The C-terminal region of 
ImuB immediately after the predicted β-clamp binding motif 354QLPLWG359 was removed by 
introduction of a stop codon. ImuB with the C-terminus was PCR amplified using 
oligonucleotides in Table 2.5 which flanked the PCR product with EcoRI restriction site and 
cloned into the EcoRI site of the expression vector pMalc2.  
Table 2.5: List of primers for expression of ImuB, ImuA’ and C-terminally truncated 
ImuB in E. colia 
Primer Name Primer sequence 
ImuBEcoRI-F  
 
ImuA’EcoRI-F 
 
 
ImuB-Stop-1-Reverse 
 
 
ImuA’-EcoRI-Reverse 
 
ImuB-EcoRI-Reverse 
5’-ATAAAAGAATTCATGATGGCCTCCGCTCGCGTG-3’ 
 
5’-ATAAAAGAATTCATGACTGCGGCCTTCGCCTCC 
GAC-3’ 
 
5’- ATAGAATTCTCAGCCCCATAGCGGCAACTG 
CAAGCCT-3’ 
 
5’-ATAGAATTCTCACCGTCCACGCCCGTT-3’ 
 
5’-ATA GAA TTC TCA TTC GTA GCT TCC CAC-3’ 
 
aRestriction sites underlined 
 
2.5 Yeast two hybrid (Y2H) analysis 
Protein-protein interactions were assessed using the Clontech Matchmaker® Y2H system as 
per the manufacturer’s instructions. Briefly, strains carrying plasmid to be assessed were 
grown in SD-LT broth to an OD600 of 0.2 then spotted on different SD media with increasing 
stringency to identify interacting partners. ImuB fused to GAL4 binding domain (BD) 
resulted in auto activation on low-stringency growth medium; therefore, all interactions 
involving ImuB were analyzed from experiments utilizing an ImuB GAL4 activation domain 
(AD) fusion construct only. All other proteins were cloned as both BD and AD GAL4 
fusions. 
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2.6 DNA damage-induced mutagenesis assay 
UV-induced mutation frequencies were determined as described previously (Boshoff et al., 
2003; Warner et al., 2010). Briefly, M. smegmatis cultures were grown to mid-log phase 
(OD600 0.4 -0.6) in 40 ml of 7H9 broth. An aliquot of 1 ml was sampled which served as the 
untreated control, and was serially diluted for plating. The remaining 39-ml culture was 
centrifuged at 4500 rpm (3900 × g) at room temperature for 10 min and re-suspended in 5 ml 
of 7H9 broth. The suspension was transferred into sterile empty Petri dishes and treated with 
UV at 250 mJ/cm2 using a UV Stratalinker 1800 (Stratagene). The treated cells were 
transferred into a flask and fresh 7H9 broth added to 40 ml to recover at 37ºC with 1 ml of 
culture was sampled at 4.5 h and 24 h post-UV treatment. The sampled culture was serially 
diluted, and 10-5 to 10-7 dilutions were plated on 7H10 agar plates and 400 µl of the undiluted 
culture plated on 7H10 OADC medium supplemented with 200 µg/ml Rif. Colony forming 
units (CFUs) were scored after incubation at 37ºC for 3-5 days. The frequency of Rif 
resistance (RifR) was calculated as described (Warner et al., 2010). 
2.7 DNA damage sensitivity assays 
This assay was performed in parallel with the DNA damage-induced mutagenesis assay 
(Section 2.6. The culture was sampled before UV treatment and ten-fold serial dilutions (up 
to 10-7) were spotted on 7H10 medium supplemented with different concentrations of 
mitomycin C (MMC). The plates were incubated at 37ºC for 3-5 days and images of the 
plates taken using GelDoc under white light (G-Box). 
2.8 Protein extraction, quantification and detection 
2.8.1 Protein extraction from M. smegmatis 
M. smegmatis strains expressing epitope-tagged proteins were grown in 100-ml cultures to 
mid log-phase (OD600 0.4-0.6) and split into two equal 50-ml culture volumes. One aliquot 
was exposed to UV irradiation as described in section 2.7, and after irradiation, was allowed 
to recover for 1 h, whereas the other aliquot was used as an untreated control. Cells were 
harvested by centrifugation at 4500 rpm (3900 × g) for 15 min and re-suspended in 5 ml of 
7H9 broth. The suspension was transferred into a sterile Petri dish and treated with UV at 250 
mJ/cm2 using UV Stratalinker 1800 (Stratagene). Both the treated cells and untreated control 
were incubated at 37ºC with shaking for 1 h. The method of Papavinasasundaram and 
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colleagues(Papavinasasundaram et al., 2001) was adopted for protein extraction with minor 
modifications (Bhowmik et al., 1987), as follows.   
Cells were collected by centrifugation and washed three times in Z٭ buffer without β-
mercaptoethanol (60 mM disodium hydrogen phosphate, 40 mM sodium phosphate, 10 mM 
potassium chloride, 1 mM magnesium sulfate) then re-suspended in 350 µl of Z٭ buffer 
supplemented with complete mini protease inhibitor cocktail (Roche). The cells were lysed 
three times for 45 s at speed 6 using the Savant Fastprep FP120 ribolyser, with 5 min 
intervals between pulses while cooling cells on ice. For whole-cell fractions, SDS-PAGE 
loading dye was added directly to the lysed cells and boiled at 95ºC for 20 min. For soluble 
fractions, the cells were centrifuged for 20 min at room temperature (13200 rpm; 16 100 × g) 
and supernatant (soluble fraction) collected in a fresh tube and to the pellet SDS-PAGE 
loading dye added for insoluble fraction. The protein concentration of each sample was 
quantified using the Bradford Protein Assay as per manufacture’s instruction (Bio-Rad).  
2.8.2 Protein analysis by SDS-PAGE and Western blotting 
Equal amounts of protein from the soluble insoluble fractions (described in Section 2.8.1) 
were resolved on two 10% SDS-PAGE gels. One gel was stained with Coomassie brilliant 
blue stain (R250) to visualize protein, and the other, proteins transferred to a PVDF 
(Amersham) or nitrocellulose membrane (Thermo Scientific). The membrane was incubated 
with the anti-FLAG M2 antibody (Sigma) and FLAG-tagged proteins were detected using the 
ProteoQwestTM chemiluminescent Western blotting kit (Sigma). 
2.8.3 Expression and purification of recombinant ImuB and ImuA’ in Escherichia coli 
Small-scale analysis of protein expression  
E. coli BL21 (DE3) strains carrying vectors for expression of recombinant ImuB, ImuA’ and 
ImuBstop1 were inoculated in 10 ml of LB broth supplemented with appropriate antibiotics 
for plasmid maintenance. Cells were allowed to grow to an OD600 of 0.5-0.7 at 37ºC with 
vigorous shaking (Labcon Shaking Incubator).  IPTG was added to a final concentration of 
0.5 mM, and the cultures incubated at 30ºC in a New Brunswick Scientific Innova 400 shaker 
for a further 3-5 hours. To obtain a whole-cell fraction, an aliquot of 100 µl was transferred 
into a tube and centrifuged to collect the cells. The cells were re-suspended in SDS-PAGE 
loading dye and stored at -20ºC until needed. To obtain a soluble fraction, cells were 
harvested from 2 ml of culture by centrifugation (2 min at 13200 rpm; 16 100 × g). The cells 
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were re-suspended in 500 µl of column buffer (20 mM Tris-hydrochloride, pH 7.5, 200 mM 
sodium chloride, 1 mM EDTA) and lysed by sonication (Soniprep 150 High Intensity 
Ultrosonic Processor, MSE, UK) with 15 s pulses separated by 15 s intervals while cooling 
on ice. Sonication was continued until the cells had completely lysed. The lysate was then 
centrifuged for 20 minutes at 4ºC to collect the cell debris. The supernatant, containing the 
soluble protein fraction, was transferred into a fresh tube, and the pellet was retained for 
analysis of the insoluble protein fraction. The concentration of the protein in the soluble 
fraction was determined by Bradford assay. 
Equal amounts of protein from the soluble and insoluble fractions of the samples were 
resolved on 10% SDS-PAGE gels and proteins analysed as in Section 2.8.2 except that the 
fusion proteins were probed with anti-MBP primary antibody. Fusion protein was detected 
using the SuperSignal West Pico substrate (Thermo Scientific).  
Large-scale protein expression and purification 
E. coli BL21 (DE3) strains carrying vectors for expression of recombinant ImuB and ImuA’ 
were inoculated into 10 ml of LB broth supplemented with appropriate antibiotics for plasmid 
maintenance. The strains were allowed to grow overnight at 37ºC with shaking on a Labcon 
Shaking incubator. Five ml of the overnight culture was used to inoculate 1 L of LB broth 
and incubated to grow to an OD600 of 0.5-0.7 at 37ºC with shaking. Protein expression was 
induced by addition of IPTG to a final concentration of 0.5 mM and incubated at 30ºC for 3-5 
hours. Cells were collected by centrifugation at 4500 rpm for 30 min in a Beckman  Coulter 
Allegra X-22 (4250 rotor) centrifuge and re-suspended in 1 ml of column buffer 
supplemented with complete mini protease inhibitor cocktail (Roche). Cell lysis was achieved 
by sonication, as described above. The lysate was clarified by centrifugation for 20 min at 
4ºC and the supernatant was collected and stored at 4ºC for not more than 1 day prior to 
purification.  
The lysate was loaded onto a 5 ml packed amylose (New England Biolabs) column pre-
equilibrated with column buffer at 4ºC. Flow-through was collected and unbound protein 
washed with 5× column volumes of column buffer. Protein was eluted in 500 µl fractions 
with elution buffer (20 mM Tris-hydrochloride, pH 7.5, 200 mM sodium chloride, 1 mM 
EDTA, and 10 mM maltose) and protein concentration determined by monitoring absorbance 
at 280 nm (using a NanoDrop) to plot an elution profile.  Samples from all fractions were run 
on 10% SDS-PAGE gel to assess the purity of the protein. Peak fractions were pooled and 
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dialysed against low salt column buffer (20 mM Tris-hydrochloride, pH 7.5, 50 mM sodium 
chloride, 1 mM EDTA) using a dialysis tubing with 15 kDa molecular weight cut-off. The 
dialysed protein was concentrated on Millipore concentrators with a molecular weight cut-off 
of 50 kDa as per manufacturer’s instruction.  
A small-scale experiment was initially done to determine the sodium chloride concentration 
at which fusion protein can elute from a Q-Sepharose column. Briefly, 50 µl of Q-Sepharose 
resin in a round-bottomed Eppendorf tube was pre-equilibrated with the dialysis buffer (20 
mM Tris-hydrochloride, pH 7.5, 50 mM sodium chloride, 1 mM EDTA 
ethylenediaminetetraacetic acid). Two µl of concentrated protein extract, prepared as 
described above, was added and allowed to bind on ice for 2 h. The bound resin was washed 
with the same buffer five times, followed by centrifugation at 100 rpm for 1 min. The 
supernatant was collected and the bound protein eluted by sequential addition of column 
buffer containing sodium chloride at a concentration ranging from 200 mM to 3 M.  From 
this analysis, a Q-Sepharose column of 2 ml packed resin pre-equilibrated with dialysis buffer 
was loaded with concentrated protein at 4 ˚C. Flow-through was collected and washed with 
5× column volumes. Bound protein was eluted with a linear salt gradient (0.5M - 1M NaCl) 
and fractions of 500 µl collected. All fractions were analysed by monitoring absorbance at 
280nm and by gel electrophoresis on 10% SDS-PAGE gels.    
2.9 Proteomic analysis of M. smegmatis strains by mass spectrometry 
This work was done at Harvard University, School of Public Health. Preparation of peptides 
were done as follows: M.smegmatis strains were inoculated into 5 ml 7H9 broth and allowed 
to grow at 37°C with shaking until they reached stationary phase (OD600 of 1.8-2.0). The 
overnight culture was used to inoculate 100 ml of 7H9 broth and incubated until they reached 
mid-log phase (OD600 0.4-0.6). The cells were divided into two equal 50-ml aliquots where 
one was treated with UV as in Section 2.6 and allowed to recover for 1 hour. Both treated and 
untreated cells were washed three times in NSalt minimal media (100 mM Bis-Tris-
hydrochloride, 5 mM potassium chloride, 7.5 mM ammonium sulphate, 0.5 mM potassium 
hydrogen sulphate, 1 mM potassium dihydrogen orthophosphate, 10 mM magnesium 
chloride, 38 mM glycerol, pH 7.0) without Tween 80 (Garces et al., 2010). The pellet of 
washed cells was inoculated in the NSalt minimal medium and incubated overnight at 37°C. 
The cells were collected by centrifugation (13200 rpm; 16 100 × g for 10 min) and re-
suspended in 350 µl of protein extraction buffer (50 mM Tris-hydrochloride, pH 7.5, 5 mM 
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EDTA) supplemented with complete mini protease inhibitor cocktail (Roche). The 
suspension was transferred into lysing matrix B tubes and lysed on a Savant Fastprep FP120 
ribolyser for 3× (45 s at 6.5 m/s) with 5 min cooling on ice between pulses. After lysis, 2× 
tricine loading buffer (Invitrogen) was added to each sample and mixed and boiled at 95˚C 
for 30 min.  
For mass spectrometric analyses, samples were separated on a 10-20% Tricine gel 
(Invitrogen), 45 min at 100 V. Gels were destained overnight by the addition of 50% ethanol 
and 7% acetic acid, and then allowed to hydrate for 1 h in deionized water. Gels were stained 
with SimplyBlue Safe Stain (Invitrogen) for 45 min, imaged, and sliced horizontally into 
fragments of equal size based on the molecular weight markers.  
In-gel reduction, alkylation and digestion was performed after destaining and rinsing the gel 
sections with two washes of 50% ethanol and 7% acetic acid, followed by two alternating 
washes with 50 mM ammonium bicarbonate and acetonitrile. After removal of the last 
acetonitrile wash, 100 µl of sequencing grade trypsin (Promega,Madison, WI) was added to 
each gel slice at a concentration of 6.6 µg/ml in 50 mM ammonium bicarbonate/10% 
acetonitrile solution. The gel slices were allowed to swell for 30 min on ice, after which the 
tubes were incubated at 37°C for 24 h. After incubation, 100 µl of 50 mM ammonium 
bicarbonate/10% acetonitrile solution was added and incubation continued for another 24 h.  
Peptides were extracted by briefly spinning the tubes and supernatant transferred into clean 
Eppendorf tube followed by storage at 4°C. To the remaining gel slices 100 µl of 50% 
acetonitrile/0.1% formic acid was added and peptides extracted as above. The extracts were 
pooled and frozen at -80˚C before lyophilized to dryness. The dried peptide extracts are 
stable at this point and can be stored until needed.   
Processing of peptides was done by Alejandra Garces Micheal Chase (Fortune Lab) and the 
peptide samples ran at ThermoScientific Centre with the assistance of Dr. Davis Sarracino. 
Dried peptide extracts were dissolved in 40 µl of 5% acetonitrile, 0.1% formic acid and then 
loaded into a 96-well plate (AbGene) for mass spectrometry analysis on a Thermo Fisher 
Scientific Orbitrap XL, Thermo Fisher Scientific LTQ-FT or a Thermo Fisher Scientific LCQ 
Deca XP Plus, as per manufacturer’s instruction (Thermo Fisher Scientific, Waltham, 
MA).For each run, 10 µl of each reconstituted sample was injected with a FamosAutosampler 
(Dionex, Sunnyvale, CA) and the separation was performed on a 75 µM x 20 cm column 
packed with C18 Magic media (Michrom Biosciences, Auburn, CA) running at 250 nl/min 
provided from a Surveyor MS pump (Thermo Fisher Scientific) with a flow splitter with a 
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gradient of 5-60 % water 0.1 % formic acid, acetonitrile 0.1 % formic acid over the course of 
120 min. Between each set of samples, standards from a mixture of 5 angiotensin peptides 
(Michrom Biosciences) were run for 2.5 h to ascertain column performance and observe any 
potential carryover that might have occurred. The Orbitrap XL was run in a top eight 
configuration with one MS 60K resolution full scan and eight MS/MS scans. The LTQ-FT 
was run in a top nine configuration with one MS 200 K resolution full scan and nine MS/MS 
scans and the LCQ Deca XP Plus was run in a top five configuration with one MS full scan 
and five MS/MS scans. Dynamic exclusion was set to 1 with a limit of 180 seconds with 
early expiration set to 2 full scans. 
Peptide identifications were done by Micheal Chase (Fortune Lab) using the database search 
algorithm, SEQUEST (Thermo Scientific, San Jose, CA). Spectra were searched against a 
composite database contained the predicted open reading frames annotated in the genome of 
M. smegmatis mc2155. A reverse database strategy was employed to estimate false discovery 
rate (FDR) (Elias & Gygi, 2007). Peptides were filtered at a 1% FDR and clustered into 
proteins using an Occam’s approach, a strategy which produced protein identifications with 
probabilities of 0.98 or greater in parallel analyses using ProteinProphet (Nesvizhskii et al., 
2003). Spectral counts were pooled across gel slices and levels of protein expression between 
strains compared using an extended G-test (Zhang et al., 2006). 
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Chapter 3  
3. Results 
3.1 Bioinformatic analysis of DnaE2 accessory factors, ImuB and ImuA’ 
At the inception of this study, the working model (Figure 3.1) was that ImuB serves as a 
molecular adaptor, allowing DnaE2 and ImuA’ to access the replication fork via its 
interaction with the β-clamp.  
 
Figure 3.1: DnaE2-dependent mutagenesis in M. tuberculosis. According to this model, DNA 
damage causes normal replication to stall. In turn, this leads to the up-regulated expression of dnaE2, 
imuB and imuA’, which are recruited to the site of the lesion. DnaE2 and ImuA’ access the DNA 
template by interacting with ImuB which binds the β-clamp, and the complex catalyzes translesion 
synthesis across the lesion.   
As noted in the introduction, the mycobacterial C family polymerase, DnaE2, was found to 
be a DNA damage-inducible DNA polymerase and implicated in virulence and the 
emergence of antibiotic-resistant MTB mutants in vivo (Boshoff et al., 2003). Failure to 
identify a β-clamp binding motif in DnaE2 suggests that it requires another protein that is 
able to interact with the β-clamp to enable access to the replication fork. During the course of 
this study, DnaE2 was demonstrated by Dr. Warner to function with two hypothetical 
proteins, ImuB and ImuA’ (Warner et al., 2010); since they are hypothetical proteins, their 
sequences were analysed. As shown in Figure 3.2, ImuB and its M. smegmatis homologue 
(MSMEG_1622) share significant sequence similarity with E. coli DinB, a Y-family 
polymerase. However, unlike DinB, the mycobacterial ImuB homologues are characterized  
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by a C-terminus that extends beyond the 3’ terminal of β-clamp binding motif in DinB; 
moreover, ImuB lacks the catalytic residues required for polymerase function (Warner et al., 
2010). 
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Figure 3.2: Multiple sequence alignment of ImuB homologs compared to Y family polymerase 
from bacteria. The proteins were aligned using the PROMALS3D multiple sequence alignment and 
structure server (http://prodata.swmed.edu/promals3d/promals3d.php). Sequences in bold green 
denote β-clamp binding motifs. Representative sequences have magenta names and are coloured 
according to predicted secondary structures (red: α-helix; blue: β-strand). The first line in each block 
indicates conservation indices (8) for those positions with a conservation index above 4. Consensus 
secondary structure is indicated by an ׳׳ h׳׳ for α-helix and an ׳׳e׳׳ for β-strand. Consensus amino acids 
are indicated by the following symbols: conserved amino acid residues, bold uppercase letter; 
aliphatic residues, I; aromatic residues, @; hydrophobic residues, h; alcohol residues, o; polar 
residues, p; tiny residues, t; small residues, s; bulky residues, b; positively charged residues, +; 
negatively charged residues, -; charged residues, c.   
All alignments were generated with PROMALS3D bioinformatic tool (Pei et al., 2008). 
Residues shaded grey represents active-site carboxylates highly conserved among Y family 
polymerase (Ling et al., 2001). The β-clamp binding motifs were predicted with references to 
identified consensus motifs (Wijffels et al., 2005): QLSLF-for DinB proteins; -QLGL- or –
LF-for ImuB proteins. The underlined sequences were identified previously (Dalrymple et 
al., 2001). The annotation of major structural domains is derived from the crystal structure of 
the DinB homolog in S. solfataricus, Dpo4 (Ling et al., 2001), and the little finger domain of 
E. coli DNA polymerase IV  (Bunting et al., 2003). Similarly, mycobacterial ImuA and its 
homologues from other bacteria were aligned in comparison to E. coli RecA. 
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Figure 3.3: Sequence alignment of ImuA’ proteins compared to E. coli RecA protein. The 
proteins were aligned using the PROMALS3D multiple sequence alignment tool (Pei et al., 2008). 
Structural domains are drawn in bars as described in the E. coli crystal structure (Story & Steitz, 1992; 
Story et al., 1992). The shaded bars and the underlined sequence of E. coli represent the position of 
the flexible DNA binding loops, L1 and L2, in the RecA M domain.  
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ImuA’ from mycobacteria exhibit sequence similarity to the N-terminal and middle domains 
of E. coli RecA, with limited similarity in the C-terminal region (Figure 3.3). E. coli RecA 
contains phosphate-binding amino acids in the P-loop motif of the M domain but ImuA’ lacks 
such residues. M. tuberculosis ImuA’ has a shorter L1 loop and an L2 that is longer. A region 
spanning R133-R148 in the predicted ImuA’ M domain contains a number of positively charged 
residues consistent with α-helix formation and DNA binding.   
3.1.1 Prediction of ImuB and ImuA’ structures 
A homology model generated by a collaborator, Prof. Česlovas Venclovas (Laboratory of 
Bioinformatics, Institute of Biotechnology, Luthania), predicted the structure of ImuB. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: ImuB shares structural similarity with Y family polymerase from S. Solfataricus 
Dpo4. A. ImuB model is coloured according to protein chain progression from N (blue) to C-terminus 
(red), B ImuB model superimposed onto Dpo4 complexed with DNA, C. the x-ray structure of S. 
SolfataricusDpo4 complexed with DNA and incoming nucleotide (PDB id: 1jx4), D. Close-up view 
of the active site in the palm domain. 
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As shown in Figure 3.4, ImuB is structurally similar to Y-family polymerase; however, it is 
important to note that the C-terminal region extending from the β-clamp binding motif is not 
depicted in the model. A close-up view of the active site confirms the absence of catalytic 
amino acids required for DNA polymerase activity. This suggests that ImuB is a 
pseudopolymerase. The absence of the catalytic residues supports the working model that 
ImuB may play a role in allowing DnaE2 and ImuA’ to access the replication block in 
induced mutagenesis rather than in catalysis of translesion synthesis. The C-terminal 
extension of ImuB could not be modelled to any known structures suggesting that it might be 
a region with disorder. To test this interpretation, Prof. Česlovas Venclovas used the    
bioinformatic analysis tools such as, DisProt (Sickmeier et al., 2007), IUPred (Dosztanyi et 
al., 2005), DisEMBL (Linding et al., 2003) and DISOPREP (Ward et al., 2004) to predict 
regions of disorder in ImuB.  These methods predicted extensive disorder in the C-terminus 
which includes the β-clamp binding motif and the C-terminal extension (Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: ImuB has extensive disorder in the C-terminal region. The coloured rectangles 
represent disordered regions in ImuB predicted by different methods: DisProt (purple), IUPred (pink), 
DisEMBL (yellow), and DISOPRED (red).  
 
Again using homology modelling, the structure of ImuA’ was predicted by Prof. Venclovas 
using E. coli RecA as template as these proteins share significant sequence similarity. Figure 
3.6 shows that, as predicted from the sequence similarity, ImuA’ is structurally similar to a 
RecA protein in the N-terminus and middle domains, but possesses an unrelated C-terminus. 
 
 
Y polymerase-like region β-clamp motif C-terminal extension
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Figure 3.6: ImuA’ is structurally similar to E. coli RecA.  A. ImuA’ model is coloured according 
to protein chain progression from N (blue) to C terminus (red), B ImuA’ model superimposed onto E. 
coli RecA C. the x-ray structure of E. coli RecA (PDB id: 1u94). 
The data presented in this section indicate that ImuB is structurally similar to a Y family 
polymerase but has a C-terminal extension that is disordered. Moreover, the absence of active 
site acid residues characteristic of nucleotidyl transfer suggests that the protein is catalytically 
non-functional. In turn, this suggests that ImuB may function as a scaffold protein, consistent 
with the presence of a disordered C-terminal region which might allow interactions with 
other proteins. Although it has a distinct C-terminal domain, the fact that ImuA’ is 
structurally similar to RecA protein in the N-terminus and the middle domain suggests that 
ImuA’ may perform functions similar to that of RecA such as recruiting polymerase and/or 
other proteins to the site of damage (Patel et al., 2010).  
3.2. Interaction analysis of the proteins involved in the DnaE2-dependent induced 
mutagenesis pathway 
Yeast two-hybrid (Y2H) analysis (Dolan et al., 1989; Vidal & Legrain, 1999; Walhout & 
Vidal, 2001) was employed to explore the possibility that protein-protein interactions might 
determine the function of the different cassette components. In this system, genes encoding 
proteins of interest are cloned in-frame with the GAL4 activation (AD) and binding domain 
(BD) plasmids, which are then co-transformed into the yeast strain AH109. When the 
proteins interact, they bring the two domains (AD and BD) into close proximity, thus 
reconstituting a functional GAL4 transcriptional activator which drives expression of the 
downstream gene. Restoration of GAL4 function is observed by reversal of the auxotrophic 
phenotype of the host strain during growth on minimal media lacking a specific amino acid or 
A B C
ImuA’ E. coli RecA
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acids, as represented in Figure 3.7. For the experiments described below, two reporters used 
in the screen were ADE2 and HIS3. HIS3 and ADE2 are endogenous yeast genes which are 
required for the synthesis of histidine (His) and adenine (Ade), respectively. HIS3 expression 
can be scored in a growth-based assay by plating strains on media that lack histidine. Very 
small levels of expression are required for growth, and amounts of expression can be 
exquisitely modulated by exposing the yeast strain to increasing concentrations of 3-amino-
triazole (3-AT), a competitive inhibitor of the product of the HIS3 gene product, HIS3 protein 
(His3p) (Joung et al., 2000; Kennedy, 2002).  Yeast strains that lack ADE2 form red colonies 
after several days of growth on plates lacking adenine. Graded expression of ADE2 changes 
the colony colour from red to pink to white, giving a colourimetic readout that is simple to 
monitor. The drawback of using the ADE2 and HIS3 reporters is that expression levels cannot 
be easily quantified.  The ADE2 reporter alone provides strong nutritional selection and the 
use of HIS3 reporter reduces the incidence of false positives, thus allowing the control of the 
stringency of selection (James et al., 1996).  
 
Figure 3.7: Diagrammatic representation of the principle of the Yeast-two hybrid analysis. Y2H 
is based on the functional reconstitution of an intact transcriptional factor that activates reporter 
expression. The bait protein is fused to the DNA binding domain (BD) of a GAL4 transcription factor 
and the prey protein is fused to the GAL4 activation domain (AD) of the transcription factor.  When 
the bait and the prey protein physically interact when co-expressed in the host, a functional 
transcription factor is reconstituted by bringing the BD and AD domains in close proximity to activate 
expression of reporter gene by binding to the upstream activation sequence (UAS).  
3.2.1 Confirmation of pair-wise interactions between DnaN, ImuB, ImuA’, and DnaE2 
by yeast two-hybrid analysis (Y2H) 
In preliminary studies, the fusion of ImuB to the BD was found to result in auto-activation in 
the Y2H system, thus yielding a false positive signal in the plating assay.  In contrast, no 
auto-activation was observed when ImuB was cloned as an AD fusion protein.  Therefore, in 
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GAL4BD
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ADPrey
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all of the interaction analyses described below, ImuB was used solely as an AD fusion. Since 
auto-activation was not observed with any of the other constructs, all other proteins were 
used in Y2H assays in both AD and BD configurations. In previous work in our laboratory, 
Dr. Garth Abrahams had determined that the optimal concentration of 3-AT required to 
restrain background growth on synthetic drop-out (SD) medium lacking His (Durfee et al., 
1993; Kirkman-Correia et al., 1993) was 1.25 mM.   
 
Figure 3.8: Confirmation of pair-wise protein-protein interactions. PP indicates the specific 
protein-protein interaction and BD indicates the negative control where empty BD plasmid was co-
transformed with the AD-fusion plasmid. Proteins expressed in-frame with GAL4 are presented as 
AD and BD fusions, respectively. Protein interactions are observed on synthetic drop-out (SD) 
medium lacking leucine and tryptophan (SD/-LT); leucine, tryptophan and histidine (SD/-LTH); and 
leucine, tryptophan, histidine and adenine (SD-LTHA), increasing the stringency of selection. 3-AT 
was added to medium-stringency and high-stringency media in order to increase the confidence in the 
inferred interaction. 
The data in Figure 3.8 indicated that ImuB interacts with DnaE2, ImuA’ and DnaN. In 
addition, DnaN exhibits self-interaction, consistent with the function of the clamp protein as a 
homodimer (Neuwald, 2003; Stewart et al., 2001; Stukenberg et al., 1991). From these 
results, it appears that ImuA’ does not interact with DnaE2, and neither ImuA’ nor DnaE2 
interact with DnaN. This result is consistent with the working model, since it suggests that 
the interaction of ImuB with ImuA’ and DnaE2 might serve to bring these proteins to the 
replication fork through their interaction with the dnaN-encoded β-clamp. In parallel work, 
BD                PP        BD             PP         BD              PP         BD              PP
SD/-LT SD/-LTH              SD/-LTH                  SD/-LTHA
1.25 mM 3-AT         1.25 mM 3-AT 
AD-ImuB and BD-DnaN
AD-ImuB and BD-ImuA’
AD-DnaN and BD-DnaN
AD-ImuB and BD-DnaE2
AD-ImuB and BD-DnaE2AIA
AD-ImuA’ and BD-DnaE2
AD-DnaE2 and BD-ImuA’ 
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the catalytic aspartic acid residues of DnaE2 were mutated to alanines (Dr. Warner) to 
confirm that DnaE2 provides polymerase function. The mutant lacking catalytic residues 
eliminated UV-induced mutagenesis and was also hypersensitive to the genotoxic agent, 
mitomycin C (MMC), strongly implicating a direct role of DnaE2 in TLS (Warner et al., 
2010). The loss of DnaE2 function as a result of mutating an acidic active site residue was a 
very important result since it provided the first direct evidence that the C-family polymerase 
was directly involved in TLS. This finding was also consistent with the fact that ImuB lacks 
critical active site residues required for catalysis (DNA replication) which would preclude it 
from catalyzing TLS. A Y2H construct was thus generated in which the catalytic residues of 
DnaE2 were mutated (DnaE2AIA) order to investigate the possibility that this mutation 
affected the ability of DnaE2 to interact with ImuB. If this were the case, it would invalidate 
the inference that DnaE2 itself catalyzes TLS. The data in Figure3.8 show that mutating the 
catalytic residues in DnaE2 does not disrupt interaction with ImuB, further supporting the 
conclusion that the catalytic residues of DnaE2 are required for TLS function. Again, these 
results were consistent with the idea that ImuB provides the means for DnaE2 and ImuA’ to 
access DNA template through its interaction with the β-clamp. However, the nature of these 
interactions remains unknown.  
3.2.2 The β-clamp binding motif is required for interaction of ImuB with the β-clamp 
ImuB has a putative β-clamp binding motif, 354QLPLWG359, which is located in the C-
terminal region, upstream of the predicted disordered region. The presence of this motif 
identified ImuB as founder member of the DinB3 family of Y polymerases (Dalrymple et al., 
2003). To confirm the role of this motif in the interaction of ImuB with the β clamp, a 
mutated AD-ImuB fusion construct was generated in which the Gln354 residue in ImuB was 
replaced by an alanine. This construct was used to assess the effect of disrupting the 
canonical β-binding motif in ImuB on the inferred interaction with DnaN, DnaE2 and ImuA’. 
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Figure 3.9: Confirmation of the β-binding motif of ImuB. PP indicates the protein-protein 
interaction and BD indicates the negative control where empty BD plasmid was co-transformed with 
AD-fusion plasmid. Proteins expressed in-frame with GAL4 are presented as AD and BD fusions.  
As shown in Figure 3.9, this mutation specifically abolished the interaction with DnaN, 
thereby confirming the role in β-binding of the first residue in the predicted motif. Notably, 
however, this mutation did not affect the interaction of ImuB with ImuA’ and DnaE2. 
3.2.3 Y2H suggests the ability of ImuB to self-interact 
DNA Pol V is composed of two UmuD΄ subunits and a single UmuC subunit (Bruck et al., 
1996; Woodgate et al., 1989). The absence of a Pol V homologue in organisms possessing 
ImuA-ImuB-DnaE2 suggests that this cassette may represent a non-orthologous replacement 
for PolV (Jiang et al., 2009). In order to explore this possibility further, the ability of DnaE2, 
ImuB and ImuA’ to self interact was assessed by Y2H.  
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Figure 3.10: ImuB has the ability to self interact. ImuB, DnaE2 and ImuA’ were used in both AD- 
and BD-fusions. As a control for BD-ImuB auto-induction the C-terminal region of ImuB in both AD- 
and BD-fusions was eliminated. 
As shown in Figure 3.10, only ImuB appears capable of self-interaction based on the Y2H 
data. As described above (section 3.2.1), the BD-ImuB construct is associated with auto-
activation, the self-interaction observed in Figure 3.10 may be as a result of the auto-
activation of the BD-ImuB. In order to rule out this possibility a deletion of the C-terminal 
extension in the BD-fusion was tested against full length AD-ImuB and retained the ability to 
self-interact. However, when the C-terminal extension of ImuB was deleted in both AD- and 
BD-fusions eliminated the ability to self-interact. This result also indicates that ImuB self-
interaction occurs via the C-terminal extension. Since ImuB appears to be the only cassette 
component that interacts with the β-clamp, this raises the possibility that ImuB might 
function similarly to the two UmuD΄ components which are required to interact with UmuC 
to give a functional polymerase V in E. coli (Sutton et al., 2000; Sutton et al., 2001; Sutton & 
Walker, 2001).  
3.2.4 Assessment of the possibility that other proteins may be involved in this pathway  
The C-family polymerase, DnaE1, is essential for replicating the mycobacterial genome with 
high fidelity (Boshoff et al., 2003). DnaE1 was shown to be up-regulated in response to DNA 
damage although it contains no identifiable SOS box (Warner et al., 2010), suggesting that it 
might also be involved in this pathway. To investigate this possibility at the level of protein-
protein interactions, the ability of DnaE1 to bind members of the mutagenic complex was 
assessed by Y2H. 
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Figure 3.11: The involvement of DnaE1 in the DnaE2-dependent mutagenic pathway. DnaE1 
was tested in both the AD and BD fusions against the other proteins. 
Consistent with its known β-binding motif, DnaE1 was able to interact with DnaN in both 
AD- and BD-fusion configurations (Figure 3.11). Interestingly, these results suggested that 
while DnaE1 does not interact with ImuA’ or DnaE2, it is able to interact with ImuB. The 
results also show that disrupting the β-binding motif of ImuB by mutating the first residue 
(Gln354Ala) does not interfere with the interaction of DnaE1, thus indicating that the 
interaction of ImuB with DnaE1 does not involve the β-binding motif. This is surprising 
given that DnaE1 can interact with the β-clamp directly. As represented in Figure 3.12, ImuB 
is able to self-interact and there is a possibility of involvement of DnaE1 in this pathway, 
however the nature of the interactions requires further investigation.  
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Figure 3.12: Schematic representation of the summary of the Y2H data. ImuB enables DnaE2 
and ImuA’ to access the DNA template by interacting with the β-clamp and is able to self interact. 
DnaE1 also interact with ImuB when it can by itself interact with the β-clamp.  
3.2.5 Mapping of the interaction domains of ImuB and ImuA’ 
3.2.5.1 Identification of the interaction domain of ImuB 
A defined approach was adopted to map the interaction domain(s) of ImuB by progressively 
truncating ImuB from the C-terminus towards the N-terminus, thus generating a panel of 
constructs deficient in specific domains. The truncations were created by introducing 
artificial start and stop codons depicted in Figure 3.13. These constructs were then tested in 
the Y2H system for interaction with DnaE1, DnaE2, DnaN and ImuA’.  
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Figure 3.13: Multiple sequence alignment of ImuB homologues indicating the position in M. 
tuberculosis ImuB where artificial stop codons were introduced. The red line indicates the position 
where stop codons were introduced to sequentially truncate the ImuB protein. The letters in red and 
underlined indicate the β-clamp binding motif in mycobacterial ImuB and  S. solfataricus Dpo4. 
 
In the first construct, an artificial stop codon (Stop 1) was introduced immediately after the β-
clamp binding motif, creating a truncated protein which more closely resembled the DinB-
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type Y-family polymerases of E. coli and S. solfataricus (Figure 3.13). Elimination of the C-
terminal ImuB region abrogated all interactions with other proteins, except for the β-clamp 
(Figure 3.14). This was a key result, since it suggested that the C-terminal region is necessary 
for all protein-protein interactions except the ImuB-β-clamp interaction. Moreover, it 
reinforced the inferred role of the QLPLWG motif in β-clamp binding.   
 
Figure 3.14: Deletion of the C-terminal extension of ImuB eliminated interaction with other 
proteins but not DnaN. The interaction of ImuB stop 1 against other proteins was tested with ImuB 
stop 1 in the AD domain and the putative interacting partners in the BD domain.  
 
The second construct had all other domains except that both the β-clamp binding motif and 
the C-terminal extension were deleted. As shown in Figure 3.15, this abolished the interaction 
with the dnaN-encoded β-clamp as well as the interactions with the other proteins. This result 
confirmed the identity of the β-binding motif and again suggesting that that the interaction of 
ImuB with other proteins is mediated by the extended C-terminal region.  
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Figure 3.15: Deletion of the putative β-binding motif as well as the C-terminal extension 
abrogated interaction with all interacting partners. The interaction of ImuB stop 2 with other 
proteins was tested with ImuB stop 2 as an AD domain fusion and the other proteins as BD domain 
fusions.  
 
 
ImuB was then sequentially truncated further towards the N-terminus deleting the little finger 
domain and into the thumb domains generating three constructs. As above, the interaction 
with these three constructs was assessed against the other proteins. These extensively 
truncated forms of ImuB indicated no interaction with DnaE1, DnaE2, ImuA’ or the 
DnaE2AIA mutant (Figure 3.16).   
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Figure 3.16: Removal of the little finger domain into the thumb domain abrogated interactions 
with all tested proteins.  A. Deletion of the little finger domain at position 232 (Stop 3), B deletion 
into the thumb domain at position 176 (Stop 4) and C deletion into the thumb domain at position 165 
(Stop 5) amino acids.    
 
3.2.5.2 Identification of interacting domains of ImuA’ 
A similar approach was used to map the site/domain of ImuA’ with ImuB. Constructs were 
generated in which specific domains were deleted by introducing artificial start and stop 
codons (Figure 3.17).  
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Figure 3.17: ImuA’ proteins aligned indicating positions of artificial truncations. ImuA’ was 
sequentially deleted from the N-terminus at positions 32 (Start 1) and 49 (Start 2). The C-terminal 
region deleted at position 160 (Stop 1) thus creating a C-terminal deficient construct.  
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The first artificial start codon (start 1) was introduced to remove the N-terminal domain, but 
leaving the core and the C-terminal domain intact. The second start codon (start 2) was 
introduced to remove part of the N-terminus into the core domain. The C-terminal domain 
was truncated by generating a stop codon (stop 1), leaving intact N-terminal and core 
domains (Figure 3.17).  
 
Figure 3.18:  The C-terminal region of ImuA’ is critical for the interaction with ImuB. 
Interactions of ImuB with ImuA’ truncations were assessed using AD-ImuB and fusions of the ImuA’ 
constructs with the BD domain.   
From the results shown in Figure 3.18, it appears that the interaction with ImuB occurs in the 
C-terminal region of ImuA’. Mapping the interaction domain of ImuB on the C-terminus of 
ImuA’ provides some understanding of the role of ImuA’ in induced mutagenesis in that the 
N- and middle domains are similar to RecA and the C-terminus responsible for interaction 
with ImuB, suggesting a divergent form of a RecA protein that is required to form a 
mycobacterial mutasome through interaction with another component of the system.   
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Figure 3.18: Summary of the protein-protein interactions inferred from Y2H analyses. A. 
Interaction of ImuB with other proteins. Full-length ImuB is able to interact with the other cassette 
components, DnaE2 and ImuA’, as well as DnaE1 and the β-clamp. Removal of the 168 amino acid 
C-terminal region eliminates the interaction with other proteins except the β-clamp. Deletion of the β-
clamp binding motif together with the C-terminus abrogates all interactions while a single mutation of 
the first amino acid of the β-clamp binding motif eliminates the interaction with the β-clamp but not 
the other proteins. B. Full length ImuA’ interacts with ImuB only, and mutating the β-clamp binding 
motif does interfere with this interaction. Deletion of the C-terminal region of ImuA’ disrupted the 
interaction with ImuB but not the deletion of 31 and 41 amino acids on the N-terminus of ImuA’.  ND 
indicates not determined, • indicates interaction, × indicates no interaction observed and ᵒ indicates 
interactions where full-length ImuB interacted with truncated alleles.  
The data presented in Section 3.2.5 are summarised in Figure 3.18, indicating that the C-
terminal regions of ImuB and ImuA’ are important for interaction with other proteins and 
also confirming the identity of the β-clamp binding motif. However, mapping the regions of 
interactions of the accessory factors using Y2H does not indicate whether these regions are 
critical for protein function in the mycobacterial cell.  
3.3 Analysis of the imuA’-imuB/dnaE2 cassette of M. smegmatis  
In order to assess the role of the inferred protein-protein interactions in DnaE2 function, a 
combination of DNA damage-induced mutagenesis and DNA damage survival assays was 
applied. In order to survive DNA damage, cells employ TLS which can, in some cases, be 
mutagenic. This provides the rationale for assessing both survival and mutagenesis in cells 
exposed to genotoxic agents. The assays were performed in a model organism, M. smegmatis, 
which is a rapidly growing non-pathogenic mycobacterium. The genomic context of the 
imuA’-imuB/dnaE2 cassette is loosely conserved between M. tuberculosis and M. smegmatis. 
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In M. smegmatis mc2155, imuA’ and imuB are situated 10.8 kb upstream of dnaE2 whereas in 
M. tuberculosis imuA’ and imuB are located ~24.7 kb upstream of dnaE2.  However, the 
encoded proteins are highly conserved (Figure 3.2 and 3.3), and a LexA-binding site is 
located in the promoter regions of upstream of imuA’ both in M. tuberculosis (Davis et al., 
2002) and M. smegmatis. 
In order to establish whether  the interactions inferred from Y2H analyses of M. tuberculosis 
proteins apply similarly to M. smegmatis,  the Y2H analysis was repeated using the M. 
smegmatis ImuA’, ImuB, β-clamp and DnaE2 using both AD and BD domain constructs. In 
order to distinguish the proteins from M. smegmatis from those of M. tuberculosis, they are 
named MsImuA’, MsImuB, Msβ-clamp and MsDnaE2. In addition, the first catalytic residue 
of the β-clamp binding motif of MsImuB Q354A was mutated to confirm the β-clamp 
binding motif.  
 
Figure 3.19: Analysis of M. smegmatis mutagenic cassette component interactions. MsImuB as an 
AD domain fusion showed interaction with MsImuA’, MsDnaE2 and Msβ-clamp but did not show 
interaction with the other protein when used as a BD domain. This is contrary to the BD-ImuB of M. 
tuberculosis where auto-activation was observed. In another twist, the MsImuB as a BD domain 
fusion retained the interaction with Msβ-clamp but at highest stringency, the interaction was 
eliminated. The results also show that mutating the first catalytic residue of the β-clamp binding motif 
abrogates the interaction with the β-clamp, recapitulating the observations with the M. tuberculosis 
proteins.  
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3.3.1 Analysis of the DnaE2-dependent mutagenic pathway in M. smegmatis 
In accordance with established methods (Boshoff et al., 2003), DNA damage-induced 
mutagenesis was determined by measuring the frequency of emergence of rifampicin 
resistant (RifR) mutants following DNA damage. Initial analyses were performed utilizing the 
∆dnaE2 deletion mutant and its complemented derivative, ∆dnaE2 attB::dnaE2 constructed 
by Dr. H. Boshoff and described previously (Boshoff et al., 2003) as controls to validate the 
assays. The data presented in Figure 3.20 indicate that the ∆dnaE2deletion mutant is sensitive 
to DNA damage and that this phenotype is reversed in the complemented strain, confirming 
that DnaE2 is required for DNA damage tolerance in M. smegmatis. These data also indicate 
that the ∆dnaE2 mutant is impaired in the ability to form RifR mutants, and the phenotype is 
restored to wild type by complementation. 
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Figure 3.20: DnaE2 is essential for damage tolerance and induced mutagenesis in M. smegmatis. 
A. DNA damage tolerance assay of the wild type mc2155 (WT), dnaE2 deletion mutant and its 
complemented derivative, (∆dnaE2ttB::dnaE2,  following exposure to mitomycin C (MMC). Cells 
were grown to mid-log phase and ten-fold dilution’s spotted on solid medium containing different 
concentrations (0.02, 0.04, 0.06 and 0.06 µg/ml) of MMC. B. UV-induced mutation frequency to 
rifampicin resistance (RifR). Cells were grown to mid-log phase and irradiated with UV at 25 J/cm2 
before being allowed to recover in fresh medium for 24 h. At 4.5 h and 24 h post irradiation, cells 
were sampled and plated on solid medium supplemented with Rif (200 µg/ml) and the frequency of 
RifR mutants determined as a function of total viable cells. Data are from a representative experiment 
performed in triplicate.  
 
3.3.2 ImuB and ImuA’ are required for DnaE2-dependent mutagenesis in M. smegmatis 
The data in section 3.2 enabled the identification of interacting domains predicted to be 
necessary for DnaE2-dependent damage tolerance. Single knockout mutants of M. smegmatis 
lacking the homologs of ImuB and ImuA’, ∆imuA’ and imuB, respectively, as well as the 
double knockout mutant ∆imuA’-∆imuB were constructed by Dr. Warner. In parallel with the 
study described here, these mutants were used to show that deletion of either ImuB or ImuA’ 
abrogated induced mutagenesis and resulted in hypersensitivity of M. smegmatis to the DNA 
damaging agent, MMC, a phenotype that was reversed by complementation with a full-length 
copy of the relevant gene (imuA’ or imuB, depending on the deletion allele). This provided 
evidence that ImuB and ImuA’ are individually essential for DnaE2-dependent mutagenesis, 
and informed the experiments described below.  
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3.3.3 Analysis of truncated ImuB  
Y2H analyses utilizing artificially truncated proteins (Figure 3.18) indicated that the C-
terminal extension was critical for interactions with the other cassette components (DnaE2, 
ImuA’) as well as DnaE1. To determine if the C-terminus of ImuB is important for function, 
a stop codon was introduced in ImuB encoding gene to remove the 168 amino acids of the 
unstructured region immediately after the β-clamp binding motif. This allele was introduced 
by complementation at the attB site in the ∆imuA’imuB mutant strain. DNA damage induced 
mutagenesis and survival was assessed in this strain.  Deleting the C-terminal unstructured 
extension of ImuB phenocopies the ∆imuB phenotype in the presence of ImuA’ and DnaE2 
(Figure 3.21).  This indicates the equal requirement of ImuA’, ImuB and DnaE2 for induced 
mutagenesis as well as the importance of the interaction region of ImuB to allow interaction 
with other protein for function.  This result is significant as it further shows that ImuB is the 
adaptor that mediates access of the other protein to template DNA through the C-terminal 
extension.  In combination, these results imply that the ability of ImuB to interact with other 
proteins might be critical for its biological function. 
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Figure 3.21: Deletion of the C-terminal region of ImuB phenocopies the ∆imuB phenotype. (A) 
DNA damage tolerance assay and (B) UV-induced mutagenesis of the double deletion mutant 
(∆imuA’-imuB), the complemented ∆imuBattB::imuA’-imuB derivative  and two independent clones 
in which the complementing allele carried a 3-terminally truncated form of imuB that gives rise to 
with 168 amino acids C-terminal deletion (∆imuA’imuBattB::imuA’imuB∆C168.1 and 
∆imuA’imuBattB::imuA’imuB∆C168.2, respectively).  Data are from a representative experiment 
performed in triplicate.   
3.3.4 Analysis of truncated ImuA’  
The Y2H analysis described in Section 3.2.5 suggested that the C-terminal region of ImuA’ is 
important for the interaction with ImuB. To determine of the interaction observed by Y2H 
was necessary for function in M. smegmatis, the consequence of C-terminal truncation of 
ImuA’ ImuB on damage tolerance and induced mutagenesis was investigated. To do this, a 
complementation vector was constructed in which an artificial stop 1 was introduced to 
truncate ImuA’  after the middle domain eliminating the C-terminus (Figure 3.17). The 
ability of this construct to complement an ImuA’ deletion mutant was then determined in 
both induced mutagenesis and DNA damage tolerance assays.  
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Figure 3.22: The C-terminal region of ImuA’ is essential for damage tolerance and induced 
mutagenesis. (A) DNA damage tolerance assay and (B) UV-induced mutagenesis of the wild type 
mc2155 (WT), a complemented derivative of the ∆imuA’ mutant carrying full-length imuA’ 
(∆imuA’attB::imuA’), or a derivative carrying 3’-truncated imuA’ that encodes a truncated form of 
ImuA’ with 44 amino acids deleted from the C-terminus (∆imuA’attB::imuA’∆C).  Data are from a 
representative experiment performed in triplicate.   
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The data indicate that deletion of the C-terminal region of ImuA’ renders the cells sensitive to 
DNA damage; moreover, the truncated ImuA’ is unable to support induced mutagenesis 
(Figure 3.22) and so phenocopies the imuA’ gene deletion mutant (Warner et al., 2010). 
These results suggest that the C-terminal regions of both ImuB and ImuA’ are critical for 
function. Since the protein-protein interactions identified in this study also map to the C-
termini of ImuB and ImuB, the implication is that the protein-protein interactions are 
essential for function of the split mutagenesis cassette.   
3.4 Identification of other proteins involved in DnaE2-dependent damage tolerance and 
induced mutagenesis in M. smegmatis 
The unexpected protein-protein interaction observation between DnaE1 and ImuB suggested 
the possibility that other proteins might be involved in DnaE2-dependent damage tolerance. 
To explore this possibility further, a pull-down approach was designed to analyse the proteins 
involved in the DNA damage response in M. smegmatis. These methods requires tagging the 
protein of interest inside the cell with an epitope, and then subjecting the host cell to 
conditions known to induce the protein of interest and interacting partners (Phizicky & 
Fields, 1995).  
3.4.1 Introduction of a tag on the C-terminus of MsImuB 
The working model underlying this study proposed that ImuB serves as a molecular adapter 
allowing other proteins to access the damaged template DNA. Therefore, for the pull-down 
experiments, ImuB was tagged on the C-terminus with a His-FLAG tandem affinity 
purification (TAP) tag (Figure 3.23). 
 
 
Figure 3.23: Schematic representation of the TAP tag introduced on the C-terminus of 
MsImuB. A TAP tag was introduced into the C-terminus of M. smegmatis ImuB (MsImuB) in order 
to use it as in vivo bait to identify other interacting partners. The tag was introduced into a 
complementing vector in the double mutant ∆imuA’imuB background. The SOS box denotes the 
region in the operator where the LexA protein binds to control expression of down stream genes. 
Previous results had established that the ImuB C-terminal region is critical for protein-protein 
interactions  (Figure 3.14) and, in turn, for DNA damage tolerance and induced mutagenesis 
(Figure 3.21). In order to evaluate the impact of the C-terminal TAP tag on ImuB function, 
SOS 
BOX imuBimuA’
His-FLAG-Stop
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 the mutant carrying the tagged ImuB protein was applied in DNA damage tolerance and 
induced mutagenesis assays.  
 
 
 
 
 
 
 
 
 
Figure 3.24: Introduction of a FLAG-tag on the C-terminus of ImuB impairs protein function. 
(A) DNA damage tolerance assay and (B) UV-induced mutagenesis of the double deletion mutant, 
∆imuA’-imuB, the complemented strain carrying the full length imuA’-imuB region 
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(∆imuBattB::imuA’imuB), and two independent clones carrying the His-FLAG tag on the C-terminus 
of ImuB in the complementing vector (∆imuA’imuBattB::imuA’imuBCHis-FLAG_1 and 
∆imuA’imuBattB::imuA’imuBCHis-FLAG_2, respectively). Data are from a representative experiment 
performed in triplicate.   
 
The results shown in Figure 3.24 suggested that the introduction of the TAP tag appeared to 
disrupt protein function as complementation was not observed when ImuB was C-terminally 
tagged. This result was consistent with the importance of the C-terminal region of ImuB and 
suggested that the tag might interfere with the ability of ImuB to interact with other proteins 
via its C-terminal region. Based on this result, an alternative strategy, involving the N- 
terminal labelling of ImuB with a 3×FLAG tag, was then adopted. 
3.4.2 Introduction of a tag on the N-terminus of MsImuB 
 3× FLAG tag comprising the  3× DYKDDDDK (Einhauer & Jungbauer, 2001) sequence was 
introduced immediately after the start codon of MsImuB (Figure 3.25). 
 
 
 
Figure 3.25: Schematic representation of the 3×FLAG tag introduced on the N-terminus of 
MsImuB. A 3×FLAG tag was introduced on the N-terminus of MsImuB in order to use it as in vivo 
bait to identify other interacting partners. The tagged allele was introduced by complementation at 
attB site on the chromosome carried on complementing vector pAINT into the single deletion mutant 
∆imuB. The SOS box denotes the region in the operator where the LexA protein binds to control 
expression of down stream genes. 
 
The effect of the 3×FLAG tag on MsImuB function was again evaluated in DNA damage 
tolerance and induced mutagenesis assays. Unfortunately, as with the C-terminal tag, 
introduction of the tag on the N-terminus also appeared to disrupt MsImuB function (Figure 
3.26) as shown by the failure of the N-terminally tagged form of ImuB to complement the 
phenotype of the ∆imuA’-imuB mutant when carried on an integration vector with functional 
(full-length) imuA’.  
 
 
SOS BOX imuBimuA’ M-3X FLAG
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Figure 3.26: Introduction of a tag on the N-terminus of ImuB impaired protein function. (A) 
DNA damage tolerance assay and (B) UV-induced mutagenesis of the wild type mc2155 (WT), the 
∆imuA’-imuB deletion mutant, its complemented derivative, ∆imuA’-imuB attB::imuA’-imuB and two 
independent clones carrying the 3×FLAG tag on the N-terminus of MsImuB (∆imuA’imuB 
attB::imuA’imuBN3×FLAG_1 and ∆imuBattB::imuA’imuBN3×FLAG_11, respectively) inserted between the 
first and second codons of ImuB.  Data are from a representative experiment performed in triplicate.   
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Therefore, adding a tag either on the N- or C-terminus of M. smegmatis ImuB renders the 
protein non-functional. Therefore, there was no option but to select another protein as bait in 
the pull-down assay.  
3.4.3 Introduction of a tag on the N-terminus of MsImuA’ 
MsImuA’, the other member of the split imuA’-imuB/dnaE2 cassette in M. smegmatis, was 
tagged with a 3× FLAG tag preceded by a start codon on the N-terminus. The tag was 
introduced on the N-terminus because the Y2H data had implicated the C-terminus in the 
interaction of ImuA’ with ImuB, and the tagging experiments described above had shown 
that a C-terminally tagged form of MsImuB was not functional. In order to limit the impact of 
the 3×FLAG tag on potential interactions occurring on the N-terminus, it was separated from 
the N-terminus by a spacer of 7 amino acids between the tag and the second codon. The 
construct carrying the 3×FLAG tag-encoding sequence on the 5’ end of imuA’ was 
introduced into the ∆imuA’ mutant strain by integration at the attB site. 
 
Figure 3.27: Schematic representation of the 3×FLAG tag introduced on the N-terminus of 
MsImuA’. The tagged allele was introduced by complementation at attB site on the chromosome 
carried on complementing vector pAINT into the single deletion mutant ∆imuA’. The SOS box 
denotes the region in the operator where the LexA protein binds to control expression of downstream 
genes. 
 
The impact of the N-terminal tag on MsImuA’ function was again evaluated in DNA damage 
tolerance and induced mutagenesis assays. In this case, introduction of the tag on the N-
terminus of MsImuA’ did not disrupt the function of the protein (Figure 3.28) as shown by 
the restoration of MMC sensitivity and UV-induced mutagenesis to wild type levels by N-
terminal tagged MsImuA’. Incorporation of the tag as an in-frame fusion with ImuA’ was 
confirmed by DNA sequencing. 
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Figure 3.28: The function of ImuA’ with an N-terminal 3× FLAG tag was maintained. (A) DNA 
damage tolerance assay and (B) UV-induced mutagenesis of the wild type mc2155 (WT), single 
deletion mutant (∆imuA’) and the strain carrying the tagged allele on the N-terminus 
∆imuA’attB::imuA’N3×FLAG preceded by a start codon.  Data are from a representative experiment 
performed in triplicate.   
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3.5 Pull-down analysis of N-terminally ImuA’ in M. smegmatis 
Since the introduction of the tag did not appear to affect MsImuA’ function, the strain 
expressing the N-terminally tagged protein was selected for pull-down assays with the aim of 
identifying other interacting partners of this protein. Prior to conducting the pull-down 
experiment, a Western blot analysis of the tagged ImuA’ was performed to determine 
whether the tagged protein could be detected in a cell extract of M. smegmatis. The tagged 
strain was grown to mid-log phase and divided into two equal volumes: one of these was 
exposed to UV radiation to induce expression of genes, while the other was not exposed to 
UV and served as an untreated (non-induced) control. Both UV-irradiated and control 
samples were allowed to recover in normal media for 1 h, after which proteins were 
extracted, and separated by SDS-PAGE. Western blot analysis using M2 anti-FLAG antibody 
as probe was performed (Figure 3.29). The only protein detected in the western blot was the 
49-kDa FLAG-BAP control (Figure 3.29, lane 7). A protein of the expected size of 34-kDa of 
the tagged ImuA’ was not detected in any of the protein extracts from cultures of the various 
strains, with or without UV irradiation.   
 
 
 
 
 
 
 
 
 
 
Figure 3.29: Tagged ImuA’ was not detected by western blot analysis of whole-cell extracts of 
M. smegmatis. A. SDS_PAGE of whole-cell extracts of the various strains. B. Western blot analysis 
of the proteins transferred to nitrocellulose membrane and probed with M2 anti-FLAG antibody.  
Lane 1, WT, untreated control; lane 2, WT, UV-irradiated; lane 3, ∆imuA’, untreated control; lane 4, 
∆imuA’, UV-irradiated; lane 5, ∆imuA’attB::imuA’N3×FLAG untreated control; lane 6, 
∆imuA’attB::imuA’N3×FLAG, UV-irradiated; lane 7, 49-kDa FLAG-BAP control.  M denotes the 
molecular weight marker. 
 
Failure to detect the protein by western blot could be attributed to the level of expression 
since imuA’ was expressed from its native promoter. Previous work in the lab (Warner et al., 
2010) had established that transcript levels of M. tuberculosis imuA’ are very low, even 
M       1        2       3      4       5       6      7      M
250 kDa
130 kDa
100 kDa
70 kDa
55 kDa
35 kDa
25 kDa
15/10 kDa
49 kDa
A B
79 
 
following UV irradiation, in contrast to imuB which has a much higher basal level of 
expression (2% of that of sigA) and is very significantly induced following DNA damage 
(Figure 3.30).  
 
 
Figure 3.30: Schematic presentation of the transcript levels of ImuA’ and ImuB pre- and post 
UV radiation in M. tuberculosis. The values below the imuA’ and imuB genes represent normalized 
transcript levels of the corresponding genes in M. tuberculosis, and are based on the qRT-PCR 
analysis performed by Dr. B. Kana, as reported  (Warner et al., 2010). A value of “100” in this 
context corresponds to a transcript level that is 1% of that of sigA. Therefore, the level of imuA’ 
transcript in M. tuberculosis, 6 hours after UV irradiation is only 0.3% of that of sigA.  
 
The implication, based on the M. tuberculosis expression data, is that MsImuA’ is present at 
very low levels in M. smegmatis, even following DNA damage induction, and could therefore 
not be detected by Western blot analysis. Adding to the limitation of detection is that the 
3×FLAG sequence incorporated was based on the original FLAG tag sequence 
(DYKDDDDK), whereas the M2 anti-FLAG antibody has been optimized for the modified 
FLAG sequence (DYKDHD) (Hernan et al., 2000). In spite of these limitations, a 
preliminary pull-down experiment was nonetheless attempted to ascertain whether tagged 
ImuA’ might still allow the identification of its interacting proteins. In this experiment, wild 
type M. smegmatis and the ∆imuA’attB::imuA’N3×FLAG mutant were grown to mid-log phase, 
split into equal volumes, and then either treated with UV to induce the SOS response, or left 
untreated as a control. Both induced and non-induced cultures were allowed to recover for 1 
h. The cells were lysed and protein was extracted and quantified.  Equivalent amounts of total 
protein (20 µg/µl) from each sample were loaded onto M2 anti-FLAG beads and allowed to 
bind. After several washes, bound protein was eluted by boiling the beads in the presence of 
LexA
SOS 
box imuA’ imuB
SOS 
box imuA’ imuB
1 ± 0 228 ± 35Transcript levels  normalized to sigA
before UV treatment
Transcript levels normalized to sigA
6 hours 
post UV treatment
32 ± 15 18 256 ± 1 425
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SDS-PAGE loading dye SDS-PAGE analysis suggested that all sample preparations were 
heavily contaminated with antibody, and no significant differences were observed between 
samples. Nonetheless, bands were excised from the lanes containing eluate from UV-
irradiated samples of the wild type and tagged strains for Peptide Mass Fingerprinting. The 
whole lane of each strain was divided into five slices per strain making sure that the dominant 
bands were in different gel slices. The PMF analysis (performed at the Molecular and 
Biomedical Technologies Platform of the CSIR in Pretoria) did not yield any conclusive 
results owing to contamination with antibody, which obscured the data (data not shown). 
Unfortunately, owing to time limitations, this work could not be pursued further.  
 
3.6 Proteomic analysis of M. smegmatis wild type, ∆dnaE2 and ∆dnaE2attB::dnaE2 
strains after exposure to DNA damaging conditions.   
At the inception of this study, DnaE2 was known to be responsible for induced mutagenesis 
while subsequent data indicate that DnaE2 functions with two proteins, ImuA’ and ImuB, to 
form a mutagenic cassette (Boshoff et al., 2003; Warner et al., 2010). One of the cassette 
components, ImuB, was shown to be present under normal growth conditions and massively 
up-regulated at the transcript level when exposed to DNA damage in M. tuberculosis (Warner 
et al., 2010), whereas with the other components- DnaE2 and ImuA’- are only moderately 
up-regulated. The inability to detect tagged ImuA’ by Western blot analysis of whole-cell 
extracts (Section 3.4) prompted the idea to investigate the presence of the cassette 
components by mass spectroscopy (MS) in a label-free approach. Wild type, the ∆dnaE2 
deletion mutant and the ∆dnaE2attB::dnaE2 complemented strain were used for this analysis 
to determine the ability to detect these proteins under the conditions tested. Again, the cells 
were grown to mid-log phase and split into two equal volumes, one of which was treated with 
UV and the other used as a control. Following recovery of 1 h, whole-cell fractions of both 
samples were prepared for in-gel tryptic digestion to run on LC-MS. Peptide counts of 
identified proteins were determined. Only proteins that have been shown to be 
transcriptionally up-regulated in response to DNA damage by genome-wide expression 
analysis (Boshoff et al., 2003), are shown in Figure 3.34.  
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Figure 3.31: Identification of proteins known to be up-regulated in response to UV radiation.  
Proteins involved in nucleotide excision repair proteins (NER),UvrA, UvrB, UvrD1 and UvrD2; 
Homologous recombination (HR), RecA, RuvA, RuvC; RadA is known to be involved in DNA repair; 
replicative DNA helicase DnaB; single-stranded DNA binding protein ssb protein; possible DNA 
repair exonuclease belonging to sbcD family; pyrimidine biosynthesis regulatory protein PyrR; ImuB; 
a protein containing HNH nuclease domain and LexA were identified. UV + denotes cells treated and 
UV- denotes untreated cells. Only proteins that were previously shown to be up-regualated in 
response DNA damage are shown (Boshoff et al., 2003).     
 
 
The data in Figure 3.31 show that, of the proteins identified, the majority are involved in 
NER and HR DNA repair pathway processes. The Ssb protein and helicases are required in 
replication to unwind the double-stranded DNA and to bind unwound (single-stranded) DNA 
during repair and replication. RecA and LexA were identified in this analysis. These proteins 
are the key regulators of the mycobacterial SOS response. ImuB, another component of the 
SOS regulon, was also identified. DnaE2 peptides were not detected in the wild type and 
complemented strains, and ImuA’ peptides were not detected in any of the strains. In 
contrast, ImuB was detected in all strains, with and without UV irradiation. These 
observations are consistent with expression data in M. tuberculosis, which showed that imuB 
is expressed at a comparatively high basal level (Warner et al., 2010). Interestingly, however, 
the DNA repair proteins that were identified in this experiment were not significantly up-
regulated in response to the imposed damage under the conditions tested.  
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3.7 Heterologous expression of M. tuberculosis ImuA’ and ImuB in E. coli 
ImuB and ImuA’ are annotated as hypothetical proteins, Rv3394c and Rv3395c, respectively. 
However, the combination of Y2H interaction data, as well as genetic and microbiological 
assays, had established a role for these proteins in the DNA damage response. This suggested 
that structural analysis of these proteins might further aid in elucidating their role in DnaE2-
dependent DNA damage tolerance.   
 
3.7.1 Small scale expression of ImuA’ and ImuB  
Constructs were generated to enable the expression of the M. tuberculosis proteins as E. coli 
recombinants. Genes encoding ImuB and ImuA’ were cloned in the pMALc2 expression 
vector for N-terminal tagging with a maltose binding protein (MBP). The fusion proteins, 
MBP-ImuB and MBP-ImuA’ were expressed in Escherichia coli BL21 (DE3) by induction 
with IPTG at 30ºC. Fusion proteins were identified as distinct bands corresponding to the 
theoretically determined size of the fusion proteins on SDS-PAGE gels. Further to that, the 
identified bands were confirmed by probing the fusion proteins with anti-MBP primary 
antibody, and observing bands by chemiluminescence released through the peroxidise 
reaction with the conjugated secondary antibody. According to theses analyses, both proteins 
were present in the soluble and insoluble fractions of whole-cell extracts. 
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Figure 3.32: Small-scale analysis of MBP-ImuB and MBP-ImuA’ indicates expression in 
both insoluble and insoluble fractions. A. MBP-ImuA’ expression in the insoluble (lane 3) 
and soluble fraction (lane 4). B. MBP-ImuB expression in the insoluble (lane 3) and soluble 
(lane 4) fraction (lane 3). C. Protein extract from the empty vector control showing 
expression of the MBP tag in the insoluble (lane 3) and soluble fraction (lane 4). In all gels, 
lane 2 is the uninduced control.  On the right of each gel are corresponding Western blotting 
analyses of the fusion proteins. 
 
The predicted molecular weights of the MBP, MBP-ImuA’ and MBP-ImuB were 52 kDa, 83 
kDa and 115 kDa, respectively.  Bands on SDS-PAGE gel corresponding to the predicted 
A
250 kDa
130 kDa
100 kDa
70 kDa
55 kDa
35 kDa
25 kDa
MBP-ImuA’
1         2          3          4
1        2       3     
250 kDa
130 kDa
100 kDa
70 kDa
55 kDa
35 kDa
25 kDa
1          2        3          4
MBP-ImuB
1        2     3     
B
250 kDa
130 kDa
100 kDa
70 kDa
55 kDa
35 kDa
25 kDa
MBP
1      2      3    
1           2          
C
84 
 
sizes of the fusion proteins were excised for identification by PMF. In this method proteins 
separated on SDS-PAGE gels are trypsin digested in the gel and the peptide fragments 
generated are then identified by determination of molecular masses which are used to search 
for protein identity in databases (Thiede et al., 2005). According to this analysis, MBP-ImuB 
was confirmed with 95% confidence, but MBP-ImuA’ was not confirmed.  
 
3.7.2 Large scale protein expression and purification of MBP-ImuB and MBP-ImuA’ 
Based on the results from the small-scale experiment, large-scale expression was then carried 
out for both recombinants even though the PMF analysis had only confirmed the MBP-ImuB 
fusion protein. The fusion proteins were expressed as in described in Section 3.7.1. Induced 
cells were lysed and the corresponding soluble fractions were loaded onto an amylose column 
for affinity purification chromatography. Thirty two 0.5-mL fractions were collected by 
elution with 10 mM maltose in column buffer. Two µl aliquots of each fraction used to 
determine the protein concentration by measuring absorbance at 280 nm. An elution profile 
was plotted from the determined concentration.  
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Figure 3.33: Affinity purification of MBP-ImuB. A. Elution profile of MBP-ImuB from the 
amylose column and B. SDS-PAGE gel of the soluble fractions containing the highest concentration 
of protein. Lane 1, molecular weight marker; lane 2, soluble fraction from lysate of induced cells; lane 
3, flow-through; and lanes 4-15, eluted fractions 14-24   
 
Figure 3.33 indicates that the fusion protein can bind to the amylose resin; however, many 
contaminating proteins co-eluted with the fusion protein. Even those fractions that were 
enriched for the MBP-ImuB   (e.g., in lane 5 of Figure 3.33) were relatively impure. Putative 
MBP-ImuA’ recombinant protein purified from the soluble fraction of induced cells by 
affinity chromatography was similarly associated with an excess of contaminating protein 
(Figure 3.34). In this case, a dominant band of lower molecular weight (~50 kDa) was present 
in both soluble and flow-through fractions as well as the eluted fractions. Based on its size, 
and apparent binding to the amylose column, this lower band was thought to be the MBP 
protein. This hypothesis was tested by excising this protein from the gel and subjecting it to 
PMF analysis. This analysis showed that the ~50 kDa was identified as MBP indicating that 
there might be partial degradation of the fusion protein.   
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Figure 3.34: Affinity purification of MBP-ImuA’. A. Elution profile of MBP-ImuA’ from the 
amylose column and B. SDS-PAGE gel of the soluble fractions containing the highest concentration 
of protein. Lane 1 is molecular weight marker, lane 2 is the soluble fraction, lane 3 is the flow through 
fraction and lane 4-15 is eluted fractions 14-24. 
 
Since both MBP-ImuA’ and MBP-ImuB appear to elute with contaminating proteins, further 
purification was attempted using Q-Sepharose ion exchange chromatography was attempted. 
The peak fractions were and dialysed against a column buffer containing 50 mM NaCl, after 
which the dialysed protein was concentrated using Amicon ultra centrifugal filters with a 
molecular weight cut-off (MWCO) of 50kDa In the case of MBP-ImuB, a small-scale 
experiment was done to establish the approximate concentration of NaCl required to elute the 
protein from Q-Sepharose.  Based on this analysis, a 0.5 – 1 M NaCl gradient was used to 
elute the Q-Sepharose column.  
 
The dialysed fraction was loaded onto Q-Sepharose column pre-equilibrated with the buffer 
used for dialysis. A gradient of NaCl from 500 mM to 1M concentration was used for elution 
after washing the bound protein. Thirty five fractions of 500 µl of eluate were collected and 2 
µl used to determine the protein concentration by absorbance at 280 nm.   
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Figure 3.35: Representation of the SDS
column.  Thirty five 0.5
 
The identification of IMBP
suggesting that the NaCl gradient used to elute the column was probably too shallow
3.35). Nonetheless, this experiment suggested that ion exchange chromatography using a 
steeper elution gradient potentially c
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Chapter 4  
4. Discussion 
4.1 The DnaE2-dependent mycobacterial mutasome shares functional similarities to Pol 
V 
The data presented here have afforded some insight into the DnaE2-dependent mutagenic 
pathway in mycobacteria. In particular, these analyses have established that DnaE2 function 
is dependent on the accessory factors, ImuB and ImuA’, both of which are essential for DNA 
damage survival and induced mutagenesis (Warner et al., 2010).  This is consistent with the 
observation that DnaE2 generally occurs together with homologs of ImuB in organisms 
lacking Pol V (Abella et al., 2004; Erill et al., 2006; Galhardo et al., 2005).  In mycobacteria, 
ImuB and ImuA’ are in an operon and DnaE2 is located 24.7 kb upstream of this operon of 
which their expression is regulated by LexA indicating that they all form part of the SOS 
response. These findings therefore suggest a split mutagenic cassette-dnaE2/imuA’imuB-
operating in mycobacteria that may have diverged from other organisms (Warner et al., 
2010). In many respects, these data presented here and previously provide compelling 
suggestion of functional analogy with E. coli DNA polymerase V (Boshoff et al., 2003). All 
three genes of the split imuA’-imuB/dnaE2 cassette are induced as part of the mycobacterial 
SOS response (Boshoff et al., 2003), indicating that the activity of the “mycobacterial 
mutasome” might be limited to circumstances of extreme damage.  
ImuB shares considerable structural similarity with Y-family DNA polymerases, but 
possesses a C-terminal extension containing disordered regions that are characteristic of 
unstructured protein domains (Wright & Dyson, 1999). In addition, unlike “true” Y-family 
polymerases, ImuB lacks the catalytic residues required for polymerase function; instead, 
consistent with the involvement of unstructured regions in protein-protein interactions 
(Dyson & Wright, 2005; Wright & Dyson, 1999), Y2H analyses imply that ImuB plays a key 
role – via its extended C terminal domain – in enabling DnaE2 to access the replication fork 
for TLS. Interestingly, sequence alignment shows that ImuB possess the conserved residues, 
C66 and P67, identified recently for complex formation with UmuD and RecA (Cafarelli et 
al., 2013). These residues are located in the N-terminal region that resembles structural 
similarity to Y family polymerase (Ling et al., 2001).  Consistent with the identification of 
ImuB from M. tuberculosis as a member of the DinB3-type protein, these residues are 
conserved amongst DinB-like proteins (Cafarelli et al., 2013).     
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The observation that ImuB has the ability to self-interact is reminiscent of the Pol V subunit, 
UmuD, which interacts with UmuC to constitute a functional Pol V. UmuD plays a role in 
protecting the cell from the deleterious effects of the error-prone DNA damage response 
pathway, a function that is genetically distinct from its role in SOS mutagenesis (Napolitano 
et al., 2000; Pages & Fuchs, 2002). UmuD2, together with UmuC, may act as a primitive 
DNA damage checkpoint, as they specifically inhibit DNA replication without affecting 
transcription or translation when present at high levels in cells (Murli et al., 2000). UmuD 
and UmuC slow the resumption of DNA replication after UV irradiation and therefore, the 
presence of both proteins acts in a non-catalytic manner to delay SOS mutagenesis and give 
accurate pathways such as NER time to proceed (Opperman et al., 1996; Opperman et al., 
1999). A comparatively high basal level of imuB transcript was previously observed during 
growth of M. tuberculosis under standard in vitro conditions (Warner et al., 2010).  The 
massive induction of imuB by DNA damage together with the observation that it has the 
ability to self-interact suggests that ImuB might have a similar function to UmuD2, which is 
processed to UmuD’2 to constitute an active Pol V to fully engage in SOS DNA repair. The 
finding that ImuB protein was not up-regulated in UV-irradiated M. smegmatis cells that were 
recovered for an hour post-irradiation before protein extraction either suggests that the DNA-
damaging conditions used were not sufficient to induce ImuB or that the damage was 
repaired during the recovery period and the cells were in the process of recovering at the time 
of sampling. The latter explanation is consistent with the very tight regulation of TLS 
polymerase activity observed in E. coli, where the Pol V components are rapidly degraded by 
ClpXP when no other mechanisms of survival are available, thus limiting the potential to 
introduce mutations as that would compromise the integrity of the genome (Patel et al., 
2010).    
 To further extend this analogy, UmuD has been shown to share structural characteristics with 
intrinsically disordered proteins (IDPs), which have significantly less secondary or tertiary 
structure in vitro than other proteins (Dyson & Wright, 2005; Ollivierre et al., 2010). The 
IDPs often have important biological roles in regulation as they assume precise structures 
upon interaction with their binding partners (Dyson & Wright, 2005). Structural analysis of 
UmuD’2 has revealed that it possesses extended shorter arms that are disordered from the 
unbound C-terminal globular domain (Ferentz et al., 2001; Peat et al., 1996). The data 
presented here further suggest that ImuB could be a functional analog of UmuD because of 
its apparently disordered C-terminal extension which is involved in key protein-protein 
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interactions with other components of the mutasome. Therefore, ImuB might play a role in 
regulating the commitment step to fully engage SOS DNA repair through interaction with 
other proteins involved in this pathway via its C-terminal region.   
 If DNA damage persists, the UmuD2 interacts with the RecA nucleoprotein that stimulates 
processing to remove the N-terminal domain of UmuD components to UmuD’, signaling 
commitment to SOS mediated repair by Pol V. UmuD has a DNA-binding domain as well as 
a LexA-like domain that undergoes autolytic cleavage in the presence of RecA and ssDNA. 
During this process, LexA also undergoes autodigestion de-repressing the expression of SOS 
regulated proteins committing to full-on SOS response. The data presented in this study 
demonstrated that ImuB is able to self-interact and also showed that the introduction of a tag 
at the N-terminus of ImuB disrupted its function in DNA damage tolerance and induced 
mutagenesis. Therefore, a key question that remains to be addressed is whether ImuB 
undergoes processing in mycobacteria in order to constitute a functional mutasome.   
ImuA’ shares similarity with E. coli RecA specifically in the N-terminal domains that contain 
the two DNA binding sites and the ATP binding region, but this protein lacks the 
characteristic C-terminal RecA domain, and instead, has a distinct C-terminus. ImuA’ also 
lacks the canonical, RecA-like ATP binding motif. ImuA’ also differs significantly from 
RecA in the DNA binding loops, L1 and L2 (Figure 3.3.) suggesting that ImuA’ is unable to 
bind DNA in a RecA manner. However, present in the predicted M domain of ImuA’ is a 
region spanning from residues Arg133 to Arg148 in M. tuberculosis ImuA’ that contains a large 
number of positively charged residues and is predicted to form α-helix and might be a 
candidate motif for DNA binding (Warner et al., 2010). The results presented here also 
confirm  that the C-terminal region of ImuA’ is crucial for interaction with ImuB for induced 
mutagenesis, and thus serves some kind of regulatory role analogous to the C-terminus of 
RecA, which serves as autoregulatory role, and when deleted, enhances RecA function (Cox, 
2007).  
4.2 Distinguishing features of the mycobacterial mutasome  
ImuB was originally identified as founder member of the DinB3 subfamily of Y family 
polymerases, on the basis of a defining-clamp binding motif in the C-terminal region  
(Dalrymple et al., 2003). This, together with the absence of a β-binding motif in DnaE2, 
suggested that ImuB has the potential to serve as an adaptor protein allowing DnaE2 to 
access the replication fork. The experimental data presented here are consistent with the 
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identity of the β-binding motif as 354QLPLWG359 as the Q354A mutation eliminated the 
interaction of ImuB with the β-clamp in the Y2H system. Interestingly, however, work 
carried out by Dr. Warner showed that the same mutation in M. smegmatis ImuB had no 
impact on the function of the mutasome {Warner, 2010 #14; in his parallel study, mutation of 
five of the six residues was necessary in order to cripple the function of the mutasome. This 
discrepancy is most likely due to the fact that the Y2H system only provides limited 
information on the interaction between two proteins, which in this case, form part of a larger 
protein-protein interaction network in the mycobacterial cell.  
ImuB comprises an obvious, Y family-like N-terminal region, and a C-terminal region that 
has characteristics of unstructured proteins which are often involved in protein-protein 
interactions.  The disordered C-terminal extension of ImuB suggested by homology modeling 
is consistent with the proposed role of ImuB as a “hub” protein. This type of structural 
arrangement (defined N-terminus and undefined C-terminus) is not unique, and has been 
observed in other mycobacterial proteins. For example, prokaryotic ubiquitin-like protein 
(Pup) has been shown to interact with mycobacterium proteosomal ATPase (Mpa) via the C-
terminal half of Pup which has a disordered region (Liao et al., 2009).  
The data further suggest that M. tuberculosis’s response to DNA damage is distinct in that 
DnaE1 is also able to interact with ImuB, although this replicative polymerase has a β-
binding motif and has been shown to interact with the β-clamp (Kana et al., 2010). Warner et 
al. (Warner et al., 2010) and O’Sullivan et al. (O'Sullivan et al., 2008) have shown an 
induction of DnaE1 after exposure to UV radiation and treatment to ciprofloxacin, 
respectively. The interaction between DnaE1 and ImuB is surprising. One possible 
explanation for this observation could simply be that the disordered region of ImuB is highly 
promiscuous in terms of protein-protein interaction, and that the inferred interaction with 
ImuB is a false positive result. However, if there is a genuine interaction between DnaE1 and 
ImuB, this may facilitate polymerase switching to occur after TLS has taken place. There is 
also emerging evidence of the involvement of replicative polymerases in mutagenic processes 
especially the involvement of eukaryotic high fidelity replicase Pol δ. Pol δ’s involvement in 
mutagenic processes was largely shown by sharing of subunits, Pol 31 and Pol32, which are 
essential for TLS performed by Pol ζ  (Johnson et al., 2012). This could be explained by a 
recent study done in Drosophila that showed show that replicative polymerases and TLS 
polymerases compete in double strand break repair  (Kane et al., 2012).  In this study, the 
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authors showed that TLS polymerases can function during the initial synthesis stage of 
homologous recombination repair and that they compete with Pol δ during the repair process, 
and further, that Y-family polymerase, Rev1, acts to coordinate the initial recruitment of TLS 
polymerase η, thus prevent the replicative polymerase from acting during early repair 
synthesis (Kane et al., 2012). 
4.3 Insight into the DnaE2 mutagenic pathway 
Having shown that DnaE1 also interacts with ImuB, it was plausible that other proteins may 
be involved in this pathway. Y2H was a limited technique as it allows the assessment of 
binary interactions which have been defined by the researcher, and so are biased. In order to 
confirm the interactions established by Y2H and to identify other interacting partners, a pull-
down assay was attempted. The preferred bait protein for use in the pull-down assay was 
ImuB. The gene encoding MsImuB was therefore tagged on the C-terminus with a tandem 
affinity tag. However, it was discovered that the introduction of the tag disrupted the function 
of the protein, as confirmed by the damage tolerance and induced mutagenesis phenotype of a 
mutant strain of M. smegmatis carrying C-terminally tagged ImuB. This observation 
accentuated the importance of the C-terminus of ImuB and suggested that the tag interfered 
with one or more interactions between ImuB and other protein/s that are essential for function 
of the mutasome. Switching the tag to the N-terminus also resulted in a loss of ImuB 
function. The reason for this observation is unclear, but could include interference with 
processes such as post-translational modification, analogous to that observed for UmuD. 
Studies have shown that there is competition between the RecA/ssDNA-mediated and Lon-
mediated degradation of UmuD products (Gonzalez et al., 1998; Patel et al., 2010).  These 
two degradation processes play a vital role because the RecA/ssDNA degradation provides 
the processed UmuD for TLS whereas the Lon/ClpXP degradation degrades the protein when 
not required by the cell, thus keeping the level of mutagenically active UmuD’ protein at a 
minimum. Both degradation mechanisms occur on the N-terminus of UmuD removing 24 
amino acids. Introduction of a phleyomycin resistance protein (PRP) at the N-terminus of 
UmuD indicated that the Lon degradation site is within the N-terminal region of the protein. 
In this study, the wild-type PRP itself was stable when assayed in a wild-type background, 
but when fused to UmuD, the PRP-UmuD fusion protein was unstable as it was rapidly 
degraded (Gonzalez et al., 1998).  Taken together with the idea that ImuB has a function 
similar to UmuD, it is tempting to speculate that introduction of a tag on the N-terminus of 
ImuB may have disrupted posttranslational processing– if it occurs. Therefore, a high priority 
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for future work will be to test the hypothesis that ImuB undergoes post-translational 
modification.    
As an alternate strategy for the pull-down experiment, ImuA’ was tagged instead. In this 
case, N-terminal tagging of ImuA’ did not affect its function. However, the tagged protein 
could not be detected by Western blotting using anti-FLAG antibody in extracts of M. 
smegmatis cells that had been exposed to UV irradiation. This problem is probably due to the 
low level of expression of ImuA’ even after damage induction (Warner et al., 2010), which 
would reduce the sensitivity of the pull-down assay. Unfortunately, the one pull-down 
experiment that was attempted using this protein was not successful, with heavy 
contamination with antibody being one technical problem that could potentially addressed 
using a more gentle elution method (e.g., with free FLAG petide), and low sensitivity being 
another.  
A further challenge with regards to the pull-down assay is the time at which cells can be 
harvested for protein extraction as studies in E. coli have shown that the SOS response is 
dynamic at a molecular level.  Two studies have looked at promoter activity of LexA-
repressed promoters as a measure of the dynamics of the SOS response (Friedman et al., 
2005; Shimoni et al., 2009). The first monitored promoter activity of recA, lexA and umuDC 
using a low-copy reporter plasmid in which the promoters were fused to gfp gene. On the 
basis that the rate of accumulation of GFP in a cell is proportional to the rate of transcript 
production from the promoter, the authors found that the response to DNA damage in 
individual cells is highly structured: the damaged cell accurately times and synchronizes the 
repair process, it allows temporal activation of various promoters to efficiently repair the 
damage by modulation of the level LexA repressor. This therefore limits the response level, 
thereby avoiding damage response that is too high at early stages (Friedman et al., 2005). 
The second study also looked at promoter activity of recA and concluded that predicting the 
dynamics of regulatory systems suggests a stochastic rather than deterministic process 
(Shimoni et al., 2009). Harvesting the cells at 1 h post DNA damage was taken from a study 
that identified the pattern of RecA expression in mycobacteria as a measure of induction of 
the SOS response {Papavinasasundaram, 2001 #124}. In this study the authors have shown 
that in M. smegmatis there are detectacle levels of RecA protein at 1 h post treatment with 
MMC. Both these studies show that the SOS response is dynamic and complex such that the  
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time at which cells should be harvested for protein extraction is a challenge for pull-down 
experiment.  
Trying to identify other proteins that associate with (components of) the mutasome using 
ImuA’-mediated pull-down is challenging in that DnaE2, ImuB and ImuA’ are all required 
for function of the mutasome, and based on Y2H analysis, may have to interact at some point 
for DNA damage survival as well as induced mutagenesis to occur. However, it still remains 
to be determined when these proteins interact during this dynamic process, which may also 
involve post-translational modification. In other words, do these (and other) proteins interact 
with one another simultaneously, or is there a temporal order of interactions? Therefore, the 
time at which the proteins are extracted for proteomic analysis could have a major influence 
on the outcome of a pull-down assay using one of the mutasome components as bait.  
4.4 Heterologous expression of DnaE2 accessory proteins, ImuA’ and ImuB 
The expression of recombinant forms of ImuA’ and ImuB in E. coli suitable for purification 
turned out to be very challenging. Of the expression system tested, the most promising results 
were obtained using the pMAL-c2 system, which allowed ImuB and ImuA’ to be expressed 
in E. coli as N-terminal MBP fusions. However, in both cases, the majority of the fusion 
protein was found in the insoluble fraction. Amylose affinity chromatography was used in an 
attempt to purify MBP-ImuA’ and MBP-ImuB proteins from the soluble fraction of E. coli 
cell extracts. However, the peak fractions that eluted from the affinity column were relatively 
impure, and contained many contaminating proteins. Preliminary data suggest that ion 
exchange chromatography could be used to further purify the MBP-ImuB protein; however, 
this remains to be confirmed. Proteins with disordered regions, such as ImuB, are known to 
be prone to aggregate or express in inclusion bodies therefore making it an enormous task to 
find appropriate in vitro conditions to obtain  sufficient quantities  in a soluble form, suitable 
for downstream processing (Goldstone et al., 2008; Noens et al., 2011). Various strategies 
have been employed to improve the production of problematical recombinant proteins. For 
example, proteins with disordered regions are best purified and maintained in soluble form in 
complex with their partners. An attempt was therefore made to co-express ImuB and ImuA’ 
using the pETDuet system (Novagen), but this was not successful (data not shown). There 
have also been studies that show improve expression of mycobacterial proteins in E. coli, 
such as DprE1, when co-expressed with chaperones from E. coli (GroES) and M. tuberculosis  
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(CPN60.2)  (Batt et al., 2012). It will be worth testing whether this approach will work for 
ImuB and ImuA’.   
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5. Appendices 
 
Appendix A: List of abbreviations 
Ap   Ampicillin 
ATc   Anhydrotetracycline 
ATCC  American Type Culture Collection 
bp   Base pairs 
CFU   Colony forming unit 
d   Days 
DNA   Deoxyribonucleic acid 
dNTPs  Deoxynucleotide triphosphate 
DOTS   Directly Observed Therapy – Short Course 
h   Hours 
HIV   Human Immunodeficiency Virus 
Hyg   Hygromycin 
IPTG   Isopropyl-beta-D-thiogalactopyranoside 
kb   Kilo base pair 
Km   Kanamycin 
LA   Luria-Bertani agar 
LB   Luria-Bertani broth 
MDR-TB  Multidrug-Resistant Tuberculosis 
min   Minutes 
ml   Mililitre 
OADC  Oleic acid-albumin-dextrose-catalase 
OD600  Optical density at 600 nanometre wavelength 
ORF   Open reading frame 
PCR   Polymerase Chain Reaction 
R   Resistant 
RNA   Ribonucleic acid 
Rpm   Revolutions per minute 
s   Seconds 
sdH20   Sterile distilled water 
 
TB   Tuberculosis 
TDR-TB  Totally Drug Resistant Tuberculosis 
U   Units 
XDR-TB  Extensively Drug Resistant Tuberculosis 
v/v   Volume per volume 
w/v   Weight per volume 
WHO   World Health Organization 
Y2H  Yeast two hybrid  
BD  Binding domain 
AD  Activation domain 
SD  synthetic drop-out  
T  tryptophan 
L  leucine 
H  histidine 
A  Adenine 
HIS3  Gene encoding imidazoleglycerol-phosphate dehydratase 
ADE2   Gene encoding phosphoribosylaminoimidazole carboxylase 
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lacZ  Gene encoding β-galactosidase 
attB  tRNAGly attachment site   
SD  Synthetic Drop out medium  
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Appendix B: Culture media and solutions 
 
Culture media 
 
All media was made up in one litre de-ionized water and except otherwise stated sterilized by 
autoclaving (121°C for 20 mins). 
 
Luria-Bertani Broth (LB) 
 
5g yeast, 10 g tryptone, 10 g sodium chloride 
 
Luria-Bertani Agar (LA) 
 
5 g yeast, 10 g tryptone, 10 g sodium chloride, 15g agar 
 
2TY 
5g sodium chloride, 10g yeast extract, 16g tryptone 
 
Middlebrook 7H9 
 
2 ml glycerol, 4.7g DifcoTM Middlebrook 7H9 broth 
 
Middlebrook 7H10 
 
5 ml glycerol, 19 g DifcoTM Middlebrook 7H10 agar 
 
YPD broth  
1.0 g Yeast extract, 2.0 g Peptone and 2.0 g Glucose  
YPDA  
YPD plus 0.15% agar both supplemented with 0.003% adenine. 
Synthetic Drop out medium (SD)  
6.7g Yeast nitrogen base without amino acids, 0.2 g Glucose, 20 g Bacto agar and 0.2 g drop-
out mix 
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Appendix C: attB PCR strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic representation of the PCR strategy used to confirm successful integration at 
the tRNAGly attachment site following allelic exchange 
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